ࡱ>  jl_`abcdefghiq` RbjbjqPqP::&$$$$%%%%8ı`l%T"0Fl8SSSSSSS$Xh[S%"S$$cTD$%SSXz%6% Jcmvl,RTTTp[> [P[% 0"<X^SSP^T%%%$%%%%%%$$$$$$ Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\NeNS6RoN gPlQSShandong Xinhua Pharmaceutical Company Limiteda joint stock company established in the People s Republic of China with limited liability Stock Code: 0719 2011 ANNUAL RESULTS ANNOUNCEMENTThe board of directors (the  Board ) and directors (Directors) of Shandong Xinhua Pharmaceutical Company Limited (the Company) hereby announces the audited consolidated results of the Company and its subsidiaries (the Group) for the year ended 31 December 2011. The following financial information has been prepared in accordance with Hong Kong Generally Accepted Accounting Principles (HKGAAP) and the Peoples Republic of China (PRC) accounting standards. This results announcement (the Announcement) is summarised from the annual report (the Annual Report) and investors are advised to read the full text of the Annual Report to understand the full details. The Announcement is published in Chinese and English. If there are any discrepancies between the Chinese version and the English version, the Chinese version shall prevail. I. Financial summary(i) Prepared in accordance with HKGAAP (Audited)Consolidated Income StatementItem2011 RMB0002010 RMB000 2009RMB000Revenue2,917,8602,589,447 2,295,101 Profit before tax91,272128,967 116,388 Income tax expense (13,302)(22,159)(13,008)Profit for the year77,970106,808 103,380 Non-controlling interests3,5955,509 3,693Profit attributable to owners of the Company74,375101,299 99,687 Consolidated Statement of Financial PositionItem2011RMB0002010 RMB0002009 RMB000Total assets3,017,4122,772,599 2,636,363Total liabilities(1,259,624)(1,048,367)(955,542)Non-controlling interests(39,807)(38,010)(36,318)Equity attributable to owners of the Company1,717,9811,686,222 1,644,503 Prepared in accordance with PRC accounting standards (Audited) Principal Financial DataItem2011 RMB 2010RMBChange as compared to the last year (%)2009RMBTotal operating income 2,937,528,055.33 2,614,233,634.6212.372,321,927,213.25Operating profit71,927,673.11131,701,950.29(45.39)135,909,489.78Profit before taxation93,211,526.67125,128,440.97(25.51)119,373,878.21Profit attributable to the equity holders of the Company76,023,665.5797,256,602.75(21.83)102,244,346.19Profit attributable to the equity holders of the Company after extraordinary loss54,823,601.21102,314,847.16(46.42)109,058,885.67Net cash flow from operating activities97,083,018.85173,000,248.75(43.88)344,795,891.77ItemAs at 31 December 2011RMBAs at 31 December 2010RMBChange as compared to the end of last year (%)As at 31 December 2009RMBTotal assets 3,004,190,190.682,739,564,533.499.662,626,187,060.38Total liabilities1,254,451,169.371,025,030,560.1122.38956,223,520.89Total equity attributable to equity holders of the Company1,709,932,330.071,676,523,546.191.991,633,645,846.35Capital (share)457,312,830.00457,312,830.00-457,312,830.00Principal Financial IndicatorsItem2011RMB2010RMBChange as compared to the last year (%)2009RMBBasic earnings per share0.170.21(19.05)0.22Diluted earnings per share0.170.21(19.05)0.22Basic earnings per share after extraordinary loss0.120.22(45.45)0.24Return on equity of weighted average% 4.465.81Decreased by 1.35 points6.83Return on equity of weighted average after extraordinary loss% 3.226.11Decreased by 2.89 points7.28Net cash flow from operating activities per share0.210.38(44.74)0.75ItemAs at 31 December 2011RMBAs at 31 December2010RMBChange as compared to the end of last year (%)As at 31 December 2009RMBNet assets per share attributable to equity holders of the Company3.743.671.913.57Asset-liability ratio (%)41.7637.42Increased by 4.34 points36.41(iii) Reconciliation of accounts prepared in accordance with PRC accounting standards and HKGAAPProfit attributable to owners of the CompanyRMBNet assetsRMB20112010As at 31 December 2011As at 1 January 2011Prepared under HKGAAP74,375,000.00101,299,000.001,717,981,000.001,686,222,000.00Prepared under PRC accounting standards76,023,665.5797,256,602.751,709,932,330.071,676,523,546.19HKGAAP adjustments:Deferred taxation292,334.43204,397.25(1,420,330.07)(1,711,546.19)Depreciation charge due to revaluation in previous years- - (21,300,000.00)(21,300,000.00)Provision for education fund(1,941,000.00)(1,362,000.00)9,469,000.0011,410,000.00 Surplus from revaluation for listing of H Shares- - 21,300,000.0021,300,000.00 Others-5,200,000.00- - HKGAAP adjustments total(1,648,665.57)4,042,397.258,048,669.939,698,453.81 Note: Explanation of the difference between the PRC accounting standards and HKGAAP:1. Education expenses are regarded as actual expenditure without the need of provision under HKGAAP. As at 31 December 2011, the balance of education expenses was RMB9,469,000.00 under the PRC accounting standards, and the education expenses were RMB1,941,000.00 for 2011;2. The aforesaid difference also led to the difference in the Companys deferred income tax, with the difference in accumulated deferred income tax being RMB1,420,330.07 and the deferred income tax of the current period being RMB292,334.43.II. DIVIDENDSThe Board has announced and proposed a final dividend for the year ended 31 December 2011 of RMB0.03 per share in the Company (the Share) (approximately HK$0.0368 per Share, including income tax) on 307,312,830 A Shares and 150,000,000 H Shares in issue. The proposed dividend is subject to approval by the shareholders of the Company at the Companys annual general meeting for the year 2011. An announcement in relation to the book closure period of the proposed dividend will be made in due course.III. MAIN BUSINESS AND FINANCIAL SITUATIONThe Group is mainly engaged in the development, production and sale of bulk pharmaceuticals, preparations, chemical products and other products. The profit of the Group is mainly attributable to its principal operations.Analysis of financial situation and operating results in accordance with PRC accounting standardsTotal assets of the Group as at 31 December 2011 was approximately RMB3,004,190,000, increased by approximately RMB264,625,000 or 9.66%, as compared with the figure of approximately RMB2,739,565,000 at the beginning of the year. The increase in total assets was mainly due to the increase of bank loans.Cash of the Group as at 31 December 2011 was approximately RMB299,229,000, decreased by approximately RMB104,821,000, as compared with the figure of approximately RMB404,050,000 at the beginning of the year. The decrease in cash was mainly due to the increase of projects expenses this year.Total equity attributable to the shareholders of the Company as at 31 December 2011 was approximately RMB1,709,932,000, increased by approximately RMB33,408,000 or 1.99%, as compared with the figure of approximately RMB1,676,524,000 at the beginning of the year. This increase was mainly attributable to the increase of operation profits this year.The total liabilities of the Group as at 31 December 2011 were approximately RMB1,254,451,000, representing an increase of approximately RMB229,420,000 or 22.38%, as compared with the figure of approximately RMB1,025,031,000 at the beginning of the year. The increase was mainly attributable to part of the loans obtained by the Group from the bank to ensure the supply of funds for production, operation and projects, leading to an increase in the loans.Operating profit of the Group for the year of 2011 and net profit attributable to the Companys shareholders for 2011 amounted to approximately RMB71,928,000 and approximately RMB76,024,000 respectively, representing relatively larger decreases as compared with those of the previous year. The decreases were mainly attributable to the increase in provision for impairment loss of assets this year.The Groups net decrease in cash and cash equivalents for the year of 2011 was approximately RMB100,105,000. The decrease was mainly attributable to more fund expenses on projects. Analysis under HKGAAPAs at 31 December 2011, the current ratio and the quick ratio of the Group was 115.25% and 71.96% respectively, and the rate of accounts receivable turnover (rate of accounts receivable turnover = revenue/average trade and bill receivables100%) and the rate of stock turnover (rate of stock turnover = cost of sales/average inventories100%) were 902.72% and 574.24% respectively.The Groups demand for working capital did not show significant seasonal fluctuation through the year.The Groups main source of funds was loans from financial institutions. As at 31 December 2011, the total amount of outstanding bank loans was approximately RMB688,468,000. As at 31 December 2011, cash on hand and in bank of the Group amounted to approximately RMB299,229,000 (including bank acceptance drafts deposits of approximately RMB31,263,000). As at 31 December 2011, the Group charged the land use rights in Hutianzhen, Zhangdian, to a bank for loans. The total original value of the land use rights is RMB73,109,000, net value is RMB69,575,000. The Group pledged accounts receivable US$8,179,000 to a bank for a loan of US$8,100,000. There was no other charge on the Groups assets except the above charged assets. The Group has stringent internal control systems for cash and fund management to strengthen its financial management. The Group maintained a good level of liquidity and had strong debt repayment ability.The Group did not have any significant investment, acquisitions or asset disposals during this reporting period.As at 31 December 2011, the number of staff employed by the Group was 6,014, and the total amount of salaries and wages for 2011 was approximately RMB185,633,000.The debt-to-capital ratio of the Group was 40.07% (debt-to-capital ratio = total borrowings / equity attributable to owners of the Company 100%).The bank balance of the Company will mainly be used as working capital for production and research and development.The assets and liabilities of the Group were mainly recorded in Renminbi. For the year ended 31 December 2011, the revenue from the Groups exports was approximately US$171,406,000, which exposed the Group to certain risks associated with the fluctuation of exchange rates. Therefore, the Group has taken the following measures to lower the risks from the fluctuation of exchange rates: (1) the Group has increased the price of its export products to decrease the risks from the fluctuation of exchange rates; (2) the Group has made arrangements with overseas customers when entering into significant export contracts that the risks associated with the fluctuation in exchange rates shall be borne by both parties if the fluctuation exceeds the range of exchange rate fluctuation agreed by both parties.IV. business reviewIn 2011, the Group centred on its principal guideline of changing the mode, adjusting the structure, implementing reforms and accelerating growth, overcame such adverse factors as rising power and energy prices, hiking procurement costs and appreciating Renminbi, seized opportunities in the market and ensured steady production and operation. Looking back to 2011, the Group made the following achievements: 1. Extensive progression of structural adjustment to for long-term corporate development The Group continued to expand investment in research and development and attached great importance to research and development of new products and application of relevant results. During 2011, the Company obtained 1 new drug certificate for pazufloxacin mesylate, 3 approvals for production, completed clinical testing of calcium polycarbophils and tablets, completed 2 production handover projects, 18 mid-scale trial production projects and 14 small-scale trial production projects, obtained 14 authorized patents and had 70 projects under research. The Group achieved certain results in parks building. The technical renovation project regarding the aspirin series of products at Hutian Park has been fully completed and put into trial operation. We have commenced construction of the technical renovation project regarding the analgin series of products, and will commence construction of the technical renovation project regarding the hormone series of products in the fourth quarter. Projects including pyrazolone capacity expansion were progressing smoothly at Shouguang Park. All the parks showed an orderly growth momentum. New headway was made in capital operation. The Company preliminarily put in place the rules system and organizational system for capital operation and determined major objectives for strategic merger and acquisition. The Company completed the preliminary preparation works of the acquisition of the 100% equity interests in Shandong Tianda Bio-Pharmaceutics Co., Ltd. during the year, and completed the acquisition in early 2012, thus ending its history of lacking powder injections. 2. Reinforced focus on marketing and boosting of products market share By seizing opportunities in the market and proactively expanding product exports, the Company recorded revenue from product exports of US$171,406,000 for 2011, representing an increase of 23.36% over last year, and 6 products of the Company posted an annual export amount of more than US$10 million. Remarkable results were achieved particularly in the development of new products. Sales of L-dopa and calcium polycarbophil more than doubled as compared with last year. Upon passing the on-site audit of the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, the Company commenced to export its preparation products to the markets under the European Union. This marked a milestone in the development history of the Company. By exerting its comprehensive competitive advantages, the Company also achieved satisfactory results in domestic sales of bulk pharmaceuticals. Sales of major products including ibuprofen witnessed relatively rapid growth. External sales of chemical segment maintained rapid growth, and a cyclic industrial chain based on the four major product series has taken shape. The Company pushed ahead with its extensive preparations marketing strategy. Sales of major new preparation products such as l_(rabeprazole) and sOTm(glimepiride) recorded substantial increase. Our marketing teams for high-end hospitals, OTC, investment attraction and VIP customers kept growing. Among them, the clinical marketing teams for high-end hospitals grew to 150 persons, which have developed on their own over 200 second- and higher class hospitals. 3. Relentless efforts in technical breakthroughs and lower costs In 2011, the Company implemented 20 corporate-level technical breakthroughs, with raw material costs for such products as tramadol hydrochloride and meloxicam significantly reduced. The Group saved RMB13,000,000 on raw materials throughout the year. The Company pushed through 30 energy conservation projects during the year, promoted applications of some energy-saving new technologies including MVR and was awarded the "Certificate for Energy Management System Certification", the first of its kind in Shandong Province. Energy savings for the year amounted to RMB10,000,000 and energy consumption per RMB10,000 production value reached 0.279 ton of standard coal equivalent per RMB10,000, representing a year-on-year decrease of 8.5%. 4. Progressive enhancement in corporate management and boosted competitiveness L-dopa and new-line ipuprofen were granted the COS certificate and isopropyl karthikeyan antipyrine was granted the EU-GMP certificate from Federal Ministry of Health of Germany. Especially, the new tablets workshop passed the GMP inspection by the Department of Health of the United Kingdom, indicating a further boost of the Company's quality management level. The Company further enhanced its on-site management level and was awarded the honour of "On-site Management Exemplar of Industrial Enterprises in Zibo City". During 2011, in adhering to its clean production and development approach, the Company invested RMB19,700,000 and completed 25 environmental protection projects; emissions of sewage water, COD and ammonia nitrogen decreased respectively by 14.96%, 15.65% and 14.90% year on year. V. ProspectsAt present and in the coming future, there are still a number of difficulties posing challenges to corporate development, including weakening market demands, impact of the statess medicine policies on drug sales, rising manufacturing costs and ongoing disorderly competition in the pharmaceutical market. 2012 is a critical year for the Group to proceed with the "12th Five-Year Plan", with heavy relocation tasks and plenty of complications ahead. In this connection, the major tasks of the Group in 2012 are as follows: 1. Emphasizing on marketing and raising the Companys status in the pharmaceutical market The Company will focus on key products, markets and customers, aims to boost sales of new products and achieve substantial increase in new products export while maintaining the market share of its dominant products. The Group will accelerate construction of international marketing channels and networks, endeavouring to complete the establishment of a company in the United States in 2012. By fully leveraging the advantages of its products, the Company will adopt flexible sales tactics and ensure sales of exclusive and special products. By taking advantage of the growth opportunity for consolidating its internal resources and establishing a preparations division at the beginning of the year, the Company will make efforts on the long-term cultivation plan for key preparation products, exert the advantages of self-produced bulk preparation products, and maintain rapid growth of key preparation products. The Company will also strengthen development of terminals and marketing teams to build diversified marketing networks. By bringing into full play its technological advantage of precision chemical engineering and products complementary advantage, the Company will speed up large scale and series-based development of chemical products and drive substantial growth of the chemicals sector. 2. Highlight of technological progress to further invigorate corporate growth By firmly directing its research and development at anti-inflammatory, cardiovascular, and anti-tumor drugs, the Company will continuously expand investment in research and development, accelerate research and development of new products, complete product upgrading as early as possible, and enhance its research and innovation capabilities. By quickening application of scientific research results, the Company will strive to turn 8 projects into full production, complete production registration application for 11 projects, and complete mid- and small-scale trial production of a number of products within this year. While proactively promoting the application of the "four new technologies" and carrying out technical quality breakthroughs based on the "one strategy for one product" approach, the Company will do its utmost to boost products quality and lower costs. 3. Underscoring parks construction and capital operation and accelerating structural adjustment 2012 is a critical year for the Company to relocate the old production base and construct relevant parks. Starting with the relocation and imposing high standards and high quality from design to construction, the Company will firmly promote application of the "four new technologies", upgrade and renovate traditional production lines, lower costs, enhance quality, and exert its technological advantages to cater for the special demands of customers and adopt a differentiated growth approach. By well summarizing the experience from the acquisition of Shandong Tianda Bio-Pharmaceutics Co., Ltd., the Company will further clarify the development direction, actively seek new partners and accelerate the structural adjustment and upgrading of products. 4. Reinforcing corporate management and consolidating growth foundation By further optimizing its internal organizational structure, the Company will streamline the management process, strengthen professional management, and enhance the management level and operational efficiency. By carrying out the "Year of Fundamental Management" event in a deep-going way as set at the beginning of the year, and reinforcing fundamental management on all fronts, the Company will conduct self-examination and take remedial measures against the existing problems and weaknesses in fundamental and professional management so that the quality of all the staff and the level of on-site management and professional management can be further enhanced, and that major accidents relating to quality, safety and environmental protection can be eradicated. Furthermore, the Company will strengthen risk prevention and control, guard against operational risks in a practical manner and enhance operation and management quality. By fully utilizing its OA platform, K/3 system, ERP, online energy management system, the  HYPERLINK "http://www.ebnew.com" www.ebnew.com procurement website (_oc}), and other informationalized means, the Company will further raise its management efficiency and level. In 2011, with the concerted efforts of all the staff, the Group achieved steady growth in production and operation. Looking into 2012, we are confident that under the leadership of the Board of Directors of the Company, the Group, in the spirit of reform and innovation, will go all out to achieve more breakthroughs in its development during the "12th Five-Year Plan" period. VI. Important IssuesStaff and RemunerationThe Groups staff remuneration was determined in accordance with State policies, the Companys profit in the corresponding period and the average income of local residents.As at 31 December 2011, the number of staff employed by the Group was 6,014, and the total amount of their salaries and wages for the year 2011 was approximately RMB185,633,000.Purchase, Sale or Redemption of the Companys Listed SecuritiesDuring the year ended 31 December 2011, the Company did not redeem the Companys listed securities. Neither the Company nor its subsidiaries, purchased, sold or redeemed any of the Companys listed securities.Connected TransactionsSignificant connected transactions carried out in the normal course of the Groups business are summarised as follows:Item2011 RMB0002010 RMB000With immediate holding companyShandong Xinhua Pharmaceutical Group Company Limited and its subsidiariesSale of water, electricity, steam and waste materials10,66710,824 Purchase of raw materials 52,69664,408Payment of annual trademark licence fee1,1001,100Design fees income1165Rental expenses500500 Impairment losses on amounts due from fellow subsidiaries-12,474With fellow subsidiary - China Shandong Group Ltd. Sale of bulk pharmaceuticals and chemical raw materials29,057-With associatesPurchase of raw materials27629Sale of water, electricity, steam447656With minority shareholders Sale of bulk pharmaceuticals and chemical raw materials157,367130,031 Purchase of chemical raw materials and water, electricity, steam447838 In the opinion of the Directors (including the independent non-executive Directors), the above transactions were carried out in the ordinary and usual course of the Groups business and on normal commercial terms. The aggregate amount of the above transactions for each of the years 2010 and 2011 did not exceed the annual cap approved in the general meeting of the Company.AuditorsThe accounts of the Company and the Group for this year prepared in accordance with HKGAAP and PRC accounting standards have been audited by SHINEWING (HK) CPA Limited (practicing certified public accountants in Hong Kong) and ShineWing Certified Public Accountants (certified public accountants in the PRC) respectively.The Company intends to re-appoint SHINEWING (HK) CPA Limited and ShineWing Certified Public Accountants as international auditors and PRC auditors of the Company respectively for the year 2012 at the annual general meeting for the year 2011 to be held in 2012.Code on Corporate Governance PracticesThe Directors (including the independent non-executive Directors) are of the opinion that for the year ended 31 December 2011, the Company has complied with all requirements set out in the Code on Corporate Governance Practices including provisions contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.The Company has always strived to comply with the best practices of the Code on Corporate Governance Practices. Material Litigation and ArbitrationSave and except for the legal action instituted by the Group against five companies including Shandong Xinkangqi Phamaceutical Co., Ltd. for an aggregate sum of approximately RMB 60,730,000 in receivables owed to the Company by such parties (in respect of which the Company suffered has reflected in its accounts an impairment loss of RMB48,590,000 as a result thereof), the Group was not involved in any material litigation or arbitration and no material litigation or arbitration is pending or threatened or was made against the Group during the reporting period.Sale of AssetsDuring the reporting period, there were no material acquisitions and sales of assets, nor any material mergers.Amendments to the ArticlesDuring the reporting period, there were no amendments to the articles of association of the Company.Audit CommitteeThe audit committee has, together with the management, reviewed the accounting principles, practices and methods adopted by the Group and has reviewed the auditing, internal control and financial reporting of the Group. The audit committee has convened four meetings to review the audited financial statements for 2010, the unaudited 1st quarterly financial statements for 2011, the unaudited interim statements for 2011 and the unaudited 3rd quarterly financial statements for 2011.The audit committee convened a meeting on 22 March 2012 to review the 2011 audited accounts and annual results announcement.VII. FINANCIAL REPORTSThe financial reports of the Company and the Group for the financial year ended 31 December 2011 have been audited by SHINEWING (HK) CPA Limited (practicing certified public accountants in Hong Kong) and ShineWing Certified Public Accountants (certified public accountants in the PRC) in accordance with HKGAAP and PRC accounting standards respectively. In their respective auditors reports there was no qualified opinion.1. financial statement and notes Prepared Under PRC Accounting StandardsConsolidated and the Companys Income Statement for the year 2011 (AUDITED) Unit: RMBItem20112010Consolidated The CompanyConsolidatedThe Company1.Total operating income2,937,528,055.331,805,458,124.222,614,233,634.621,666,209,845.12 Includes: Operating income2,937,528,055.331,805,458,124.222,614,233,634.621,666,209,845.122.Total operating costs2,874,617,794.851,749,515,071.832,490,856,909.691,591,954,358.06 Includes: Operating cost2,391,580,913.171,533,694,893.062,133,691,060.291,370,885,913.46 Taxes and surcharges13,158,975.169,000,247.7014,693,182.5012,042,077.26 Selling expenses199,663,018.5722,897,050.70129,471,309.2026,392,447.32 Administrative expenses176,046,032.51145,042,121.62165,142,770.60134,908,546.18 Financial expenses37,268,918.2336,971,658.5321,701,647.0623,458,453.18 Assets Impairment loss56,899,937.211,909,100.2226,156,940.0424,266,920.66 Add: Gain or loss from changes in fair value---- Investment gain or loss9,017,412.6310,509,738.648,325,225.3611,858,268.38 Includes: Investment gain or loss from related ventures and joint ventures5,140,685.085,140,685.085,259,770.205,259,770.203. Operating profit71,927,673.1166,452,791.03131,701,950.2986,113,755.44 Add: Non-operating income32,370,741.3126,378,632.2910,041,631.625,190,633.15 Less: Non-operating cost11,086,887.757,352,654.8516,615,140.9415,306,112.32 Includes: Loss from the disposal of non-current assets3,910,059.763,858,833.7313,424,913.3813,404,692.704. Profit before taxation93,211,526.6785,478,768.47125,128,440.9775,998,276.27 Less: Income tax expense13,592,585.9211,247,672.8522,362,744.9010,513,609.305. Profit after taxation79,618,940.7574,231,095.62102,765,696.0765,484,666.97 Includes: Profit attributable to the equity holders of the Company76,023,665.57-97,256,602.75- Minority interest3,595,275.18-5,509,093.32-6. Earnings per share 1) Basic earnings per share0.170.160.210.14 2) Diluted earnings per share0.170.160.210.147.Other comprehensive income(20,051,251.32)(19,188,362.40)(37,036,620.68)(36,112,737.05)8. Total comprehensive income59,567,689.4355,042,733.2265,729,075.3929,371,929.92 Includes: Total comprehensive income attributable to the equity holders of the Company56,274,425.38-60,543,341.34- Total comprehensive income attributable to minority interest3,293,264.05-5,185,734.05- Financial Notes:1. During this reporting period, there was no change in accounting policies, accounting estimates or corrections of accounting errors of the Company.2. During this reporting period, there was no change in the scope of consolidation of the Company.2. financial statements AND NOTES PREPARED UNDER HKGAAPCONSOLIDATED INCOME STATEMENTNOTES20112010RMB000RMB000Revenue32,917,8602,589,447Cost of sales(2,369,697)(2,108,507)Gross profit548,163480,940Investment income4,1055,625Other income46,33521,884Other expenses(34,658)(35,187)Distribution and selling expenses(214,103)(145,900)Administrative expenses(235,613)(184,500)Finance costs4(28,098)(19,155)Share of profit of an associate5,1415,260Profit before tax91,272128,967Income tax expense5(13,302)(22,159)Profit for the year677,970106,808Profit for the year attributable to:Owners of the Company74,375101,299Non-controlling interests3,5955,50977,970106,808Earnings per share basic and diluted8RMB0.163 RMB0.222CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 20112010NOTERMB000RMB000Profit for the year77,970106,808Other comprehensive (expense) income: Exchange differences arising on translation of a foreign operation(864)(924) Fair value loss arising on available-for-sale investments (22,574)(42,432)Reclassification adjustments for the cumulative gains included in profit or loss upon disposal of available-for-sale investments-(54)Income tax relating to components of other comprehensive income3,3866,373Other comprehensive expense for the year, net of tax(20,052)(37,037)Total comprehensive income for the year57,91869,771Total comprehensive income attributable to:Owners of the Company54,62564,585Non-controlling interests3,2935,18657,91869,771CONSOLIDATED STATEMENT OF FINANCIAL POSITIONNOTES20112010RMB000RMB000Non-current assetsProperty, plant and equipment1,065,5211,007,323Construction in progress363,330120,261Prepaid lease payments on land use rights217,022222,703Investment properties37,14235,707Interest in an associate21,76116,620Available-for-sale investments136,072158,646Deferred tax assets16,5883,418Prepayments for acquisition of land use rights31,7879,6521,889,2231,574,330Current assetsInventories423,789401,543Trade and other receivables9389,356375,963Prepaid lease payments on land use rights5,7115,741Amounts due from fellow subsidiaries6,60037Tax recoverable3,5041,289Pledged bank deposits31,26335,980Bank balances and cash267,966368,0701,128,1891,188,623Assets classified as held for sale-9,6461,128,1891,198,269Current liabilitiesTrade and other payables10485,119490,302Dividend payables15,11113,612Amounts due to fellow subsidiaries2,8356,087Amount due to an associate612Tax payable6083,061Borrowings475,147200,000978,881713,064Liabilities associated with assetsclassified as held for sale-1,166978,881714,230Net current assets149,308484,039Total assets less current liabilities2,038,5312,058,369Capital and reservesShare capital457,313457,313Reserves1,246,9491,206,043Proposed final dividend13,71922,866Equity attributable to owners of the Company1,717,9811,686,222Non-controlling interests39,80738,010Total equity1,757,7881,724,232Non-current liabilitiesDeferred tax liabilities5,5702,871Borrowings213,321275,528Deferred income61,85255,738280,743334,1372,038,5312,058,369NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNDER HKGAAP1. BASIS OF PREPARATIONThe audited consolidated financial statements are prepared in accordance with Hong Kong Financial Reporting Standards (HKFRSs), Hong Kong Accounting Standards (HKASs) issued by Hong Kong Institute of Certified Public Accountants (HKICPA) and the disclosure requirements of Appendix 16 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.2. APPLICATION OF NEW AND REVISED HKFRSsIn the current year, the Company has applied the following new and revised standards, amendments and interpretations (INTs) (herein collectively referred to as new and revised HKFRSs) issued by the Hong Kong Institute of Certified Public Accountants (the HKICPA).HKFRSs (Amendments)Improvements to HKFRSs issued in 2011 except for the amendments to HKFRS 3 (as revised in 2008), HKFRS 7, HKAS 1 and HKAS 28HKFRS 1 (Amendment)Limited Exemption from Comparative HKFRS 7 Disclosures for First-time AdoptersHKAS 24 (Revised)Related Party DisclosuresHong Kong Accounting Standard (HKAS) 32 (Amendment)Classification of Rights IssuesHK(IFRIC)-INT 14 (Amendment)Prepayments of a Minimum Funding RequirementHK(IFRIC)-INT 19Extinguishing Financial Liabilities with Equity InstrumentsHKAS 24 Related Party Disclosures (as revised in 2009)HKAS 24 Related Party Disclosures (as revised in 2009) modifies the definition of a related party and simplifies disclosures for government-related entities.The disclosure exemptions introduced in HKAS 24 (as revised in 2009) will affect the Group because the Group is a government-related entity. As the Group had no significant operating transactions with other government-related entities, the revised standards have no material impact on the Groups presentation.The application of the other new and revised HKFRSs had no material effect on the consolidated financial statements of the Group for the current or prior accounting periods.The Group has not early applied the following new and revised standards, amendments or interpretations that have been issued but are not yet effective.HKFRS 1 (Amendment)Severe Hyperinflation and Removal of Fixed Dates for First-time Adopters1HKFRS 7 (Amendment)Financial Instruments: Disclosures Transfers of Financial Assets1HKFRS 7 (Amendment)Disclosures Offsetting Financial Assets and Financial Liabilities4HKFRS 7 (Amendment)Mandatory Effective Date of HKFRS 9 and Transition Disclosures6HKFRS 9Financial Instruments6HKFRS 10Consolidated Financial Statements4HKFRS 11Joint Arrangements4HKFRS 12Disclosure of Interests in Other Entities4HKFRS 13Fair Value Measurement4HKAS 1 (Amendment)Presentation of Items of Other Comprehensive Income3HKAS 12 (Amendment)Deferred Tax: Recovery of Underlying Assets2HKAS 19 (Revised)Employee Benefits4HKAS 27 (Revised)Separate Financial Statements4HKAS 28 (Revised)Investments in Associates and Joint Ventures4HKAS 32 (Amendment)Offsetting Financial Assets and Financial Liabilities5HK(IFRIC)-INT 20Stripping Costs in the Production Phase of a Surface Mine41 Effective for annual periods beginning on or after 1 July 2011.2 Effective for annual periods beginning on or after 1 January 2012.3 Effective for annual periods beginning on or after 1 July 2012.4 Effective for annual periods beginning on or after 1 January 2013.5 Effective for annual periods beginning on or after 1 January 2014.6 Effective for annual periods beginning on or after 1 January 2015.HKFRS 9 Financial InstrumentsHKFRS 9 Financial Instruments issued in November 2009 and amended in October 2010 introduces new requirements for the classification and measurement of financial assets and financial liabilities and for derecognition.HKFRS 9 requires all recognised financial assets that are within the scope of HKAS 39 Financial Instruments: Recognition and Measurement to be subsequently measured at amortised cost or fair value. Specifically, debt investments that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortised cost at the end of subsequent accounting periods. All other debt investments and equity investments are measured at their fair values at the end of subsequent accounting periods. In addition, under HKFRS 9, entities may make an irrevocable election to present subsequent changes in the fair value of an equity investment (that is not held for trading) in other comprehensive income, with only dividend income generally recognised in profit or loss.The most significant effect of HKFRS 9 regarding the classification and measurement of financial liabilities relates to the accounting for changes in fair value of a financial liability (designated as at fair value through profit or loss) attributable to changes in the credit risk of that liability. Specifically, under HKFRS 9, for financial liabilities that are designated as at fair value through profit or loss, the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is recognised in other comprehensive income, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss. Changes in fair value attributable to a financial liability's credit risk are not subsequently reclassified to profit or loss. Previously, under HKAS 39, the entire amount of the change in the fair value of the financial liability designated as at fair value through profit or loss was recognised in profit or loss.HKFRS 9 is effective for annual periods beginning on or after 1 January 2013, with earlier application permitted.The directors anticipate that HKFRS 9 that will be adopted in the Group's consolidated financial statements for the annual period beginning 1 January 2013 and that the application of the new standard will have a significant impact on amounts reported in respect of the Groups financial assets and financial liabilities. However, it is not practicable to provide a reasonable estimate of that effect until a detailed review has been completed.Amendments to HKAS 1 Presentation of Items of Other Comprehensive IncomeThe amendments to HKAS 1 retain the option to present profit or loss and other comprehensive income in either a single statement or in two separate but consecutive statements. However, the amendments to HKAS 1 require additional disclosures to be made in other comprehensive income section such that items of other comprehensive income are grouped into two categories: (a) items that will not be reclassified subsequently to profit or loss; and (b) items that may be reclassified subsequently to profit or loss when specific conditions are met. Income tax on items of other comprehensive income is required to be allocated on the same basis.The amendments to HKAS 1 are effective for annual periods beginning on or after 1 July 2012. The presentation of items of other comprehensive income will be modified accordingly when the amendments are applied in the future accounting periods.Other than disclosed above, the directors of the Company anticipate that the application of the other new and revised standards, amendments or interpretations will have no material impact on the results and the financial position of the Group.3. SEGMENTAL INFORMATIONThe Groups operating segments, based on information reported to the board of directors of the Company, being the chief operating decision maker, for the purposes of resource allocation and assessment of segment performance focuses on the types of goods supplied. The principal types of goods supplied are bulk pharmaceuticals, preparations, chemical and other products and commerce circulations. The Groups reportable segments under HKFRS 8 are as follows:Bulk pharmaceuticals:Development, production and sales of bulk pharmaceuticalsPreparations:Development, production and sales of preparations (e.g. tablets and injections)Chemical and other products:Production and sales of chemical and other products Commerce circulations:Trading of pharmaceutical products (including retail and wholesale)Information regarding the above segments is reported below. Segment revenues and resultsThe following is an analysis of the Groups revenue and results by reportable segment.For the year ended 31 December 2011Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsEliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales1,491,589553,395734,364138,512-2,917,860Inter-segment sales11,077346,34458,129275,781(691,331)-Total 1,502,666899,739792,493414,293(691,331)2,917,860Segment profit 112,74117,220(39,034)10,208101,135Unallocated income50,440Unallocated expenses(37,346)Finance costs(28,098)Share of profit of an associate5,141Profit before tax 91,272For the year ended 31 December 2010Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsEliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales1,312,077510,628686,48180,261-2,589,447Inter-segment sales5,672377,02095,704243,403(721,799)-Total 1,317,749887,648782,185323,664(721,799)2,589,447Segment profit 117,40420,2777,8317,716153,228Unallocated income 27,509Unallocated expenses(37,875)Finance costs(19,155)Share of profit of an associate5,260Profit before tax 128,967The accounting policies of the reportable segments are the same as the Groups accounting policies. Segment profit represents the profit earned by each segment without allocation of investment and other income, other gains and losses, other expenses, depreciation for investment properties, finance costs and share of profit of an associate. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and performance assessment. Inter-segment sales are charged at prevailing market rates.Segment assets and liabilitiesThe following is an analysis of the Groups assets and liabilities by reportable segment:At 31 December 2011Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Segment assets1,300,312483,372182,817536,6152,503,116Unallocated corporate assets514,296Consolidated assets3,017,412Segment liabilities239,10391,33271,11386,467488,015Unallocated corporate liabilities 771,609Consolidated liabilities1,259,624At 31 December 2010Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Segment assets1,244,040428,056128,777342,3502,143,223Unallocated corporate assets629,376Consolidated assets2,772,599Segment liabilities268,651106,82644,90176,013496,391Unallocated corporate liabilities 551,976Consolidated liabilities1,048,367For the purposes of monitoring segment performances and allocating resources among segments:all assets are allocated to reportable segments other than deferred tax assets, interest in an associate, available-for-sale investments, investment properties, tax recoverable, pledged bank deposits, bank balances and cash and assets classified as held for sale. Assets used jointly by reportable segments are allocated on the basis of revenues earned by individual reportable segments; andall liabilities are allocated to reportable segments other than liabilities associated with assets classified as held for sale, deferred tax liabilities, borrowings, deferred income and tax payable. Liabilities for which reportable segments are jointly liable are allocated on the basis of revenues earned by individual reportable segments. Other segment informationFor the year ended 31 December 2011Amounts included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Addition to non-current assets (Note) 219,50159,3021,221182,177462,201Depreciation and amortisation (excluded depreciation for investment properties)83,97522,4901,28023,725131,470Impairment losses recognised in respect of trade and other receivables 41920,55530,6297851,681Reversal of impairment loss on trade and other receivables--(216)-(216)Reversal of allowance for inventories(6,789)(1,973)(126)(2)(8,890)Write-down of inventories1,0727677022,8995,440Note: Non-current assets excluded financial instruments, investment properties, deferred tax assets and interest in an associate. Depreciation and amortisation excluded depreciation for investment properties.For the year ended 31 December 2011Amounts regularly provided to the chief operating decision maker but not included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Interest in an associate-21,761--21,761Interest income1,592401941192,206Loss on disposal of property, plant and equipment(5,706)(1,598)(25)(4,016)(11,345)Finance costs(21,779)(6,133)(181)(5)(28,098)Income tax (expense) credit(9,819)6053,820(7,908)(13,302)For the year ended 31 December 2010Amounts included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Addition to non-current assets (Note) 91,70631,86446589,057213,092Depreciation and amortisation (excluded depreciation for investment properties)81,05927,3371,27213,787123,455Reversal of impairment loss on trade and other receivables(657)(34)--(691)Bad debts recover of trade receivables(6)(52)(62)-(120)Impairment losses recognised in respect of trade and other receivables138891,330451,602Impairment losses recognised in respect of amounts due from fellow subsidiaries12,474---12,474Write-down of inventories6,3112,593-18,905Note: Non-current assets excluded financial instruments, investment properties, deferred tax assets and interest in an associate. Depreciation and amortisation excluded depreciation for investment properties.For the year ended 31 December 2010Amounts regularly provided to the chief operating decision maker but not included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Interest in an associate-16,620--16,620Interest income1,662690197 82 2,631Loss on disposal of property, plant and equipment(9,598)(3,423)(7)(2)(13,030)Finance costs(14,015)(5,062)(77)(1)(19,155)Income tax expense(13,469)(3,367)(3,074)(2,249)(22,159)Geographical informationThe Groups customers are mainly located in the PRC, Europe, America and other countries. Revenues from external customers20112010RMB000RMB000PRC1,838,1731,701,754Europe410,081319,414America507,721439,800Others161,885128,4792,917,8602,589,447Over 99% of the Groups non-current assets are located in the PRC and therefore the analysis of non-current assets by geographical location of the assets is not presented.Information about major customersThe Groups customer base includes a wide range of different customers. In 2010 and 2011, the Group had no single customer contributed 10% or more of the Groups revenue and therefore no significant concentration of source of income from a particular customer.4. FINANCE COSTS20112010RMB000RMB000Interest on:- Bank loans wholly repayable within 5 years26,71416,486 Government loans not wholly repayable within 5 years1,2051,11227,91917,598Discount charges on bank acceptance notes1791,55728,09819,1555. INCOME TAX EXPENSE20112010RMB000RMB000PRC enterprise income tax - Current19,71924,886 - Under-provision in prior years668-20,38724,886 Deferred tax(7,085)(2,727)13,30222,159Under the Law of the PRC on Enterprise Income Tax (the EIT Law) and Implementation Regulation of the EIT Law, the tax rate of the PRC companies is 25% for both years. Pursuant to the relevant laws and regulations in the PRC, the Company was accredited as a high-tech enterprise. The accreditation is valid for three years. The Company is entitled to the preferential tax rate of 15% for a three-year period commencing from 1 January 2008 to 31 December 2010. The accreditation has been extended for three years in 2011 and the Company is entitled to the preferential tax rate of 15% for a three-year period commencing from 1 January 2011 to 31 December 2013.Pursuant to the relevant laws and regulations in the PRC, two subsidiaries operating in the PRC are entitled to exemption from the PRC income tax in the first two years from the first profit-making year, followed by a 50% reduction of the PRC income tax for the next three years. The tax charge for the year can be reconciled to the profit before tax per the consolidated income statement as follows: 20112010RMB000RMB000Profit before tax 91,272128,967Tax at the domestic income tax rate of 25% (2010: 25%)22,81832,242Effect of preferential tax rate in the PRC(8,354)(7,282)Effect of tax exemption granted to PRC subsidiaries(827)(969)Tax effect of share of profits of associates(771)(789)Tax effect of income not taxable for tax purpose(285)(1,236)Tax effect of expenses not deductible for tax purposes80597Tax effect of additional allowance (Note)(1,272)(1,793)Tax effect of tax losses not recognised43-Tax effect of deductible temporary differences not recognised4922,025Utilisation of tax losses previously not recognised (15)(136)Under-provision in prior years668-Tax charge for the year13,30222,159Note: The amount represents the tax effect of additional tax allowance granted to the Group in respect of research and development expenditure as stipulated in the relevant tax rules in the PRC. 6. PROFIT FOR THE YEARProfit for the year has been arrived at after charging (crediting):20112010RMB000RMB000Depreciation for property, plant and equipment125,759117,597Depreciation for investment properties3,2572,688Amortisation of prepaid lease payments on land use rights5,7115,741Amortisation of technical know-how (included in administrative expenses)-117Total depreciation and amortisation134,727126,143Auditors remuneration1,1991,138Research and development costs recognised as an expense34,49217,368Operating lease rentals on land and buildings936882Impairment losses recognised in respect of financial assetstrade and other receivables (Note 9)51,6811,602amounts due from fellow subsidiaries -12,47451,68114,076Impairment loss on assets classified as held for sale -3,987Reversal of allowance for inventories (included in cost of sales)(8,890)-Write-down of inventories (included in cost of sales)5,4408,905Staff costs (excluding directors and supervisors emoluments) 252,157238,510Cost of inventories recognised as an expense2,369,6972,108,5077. DIVIDENDS20112010RMB000RMB000Dividends recognised as distribution during the year- 2010 final dividend: RMB0.05 (2010 : 2009 final dividend RMB0.05) per share 22,86622,866For the year ended 31 December 2011, final dividend of RMB0.03 (2010: RMB0.05) per share (approximately HK$0.0368 (2010: HK$0.0590) per share, including income tax of A shares) on 307,312,830 A shares and 150,000,000 H shares has been proposed by the directors of the Company and is subject to approval by shareholders at the annual general meeting and has been included as a dividend reserve in the consolidated financial statements.8. EARNINGS PER SHAREThe calculation of the basic earnings per share is based on the Groups profit for the year attributable to the owners of the Company of approximately RMB74,375,000 (2010: RMB101,299,000) and based on the weighted average number of 457,312,830 (2010: 457,312,830) shares in issue during the year.Basic earnings per share and diluted earnings per share for two years ended 31 December 2011 and 2010 are the same as there were no dilutive events existed during both years.9. TRADE AND OTHER RECEIVABLES20112010RMB000RMB000Trade and bills receivables393,531308,235Less : Allowance for doubtful debts of trade receivables(53,328)(1,979)340,203306,256Other receivables, deposits and prepayments58,39778,835Less : Allowance for doubtful debts of other receivables(9,244)(9,128)49,15369,707Total trade and other receivables389,356375,963As at 31 December 2011, included in the trade receivables of approximately RMB107,959,000 (2010: RMB80,819,000) and approximately RMB1,826,000 (2010: Nil) is denominated in United States Dollars (USD) and Great Britain Pound (GBP) respectively.The Groups revenue from export sales is on letter of credit or documents against payment. The credit period is agreed upon in the sales contract. Except for some particular customers where payment in advance is normally required, the Group allows an average credit period of 30 days to its local trade customers and 90 days for local hospital customers. The following is an aged analysis of the trade and bills receivables net of allowance for doubtful debts of trade and bills receivables presented based on the invoice date at the end of the reporting period.20112010RMB000RMB000Within one year335,408303,310More than one year but less than two years3,2122,601More than two years but less than three years1,583319Over three years-26340,203306,256Included in the Group's trade and bills receivable balance are debtors with aggregate carrying amount of approximately RMB39,684,000 (2010: RMB4,764,000) which are past due as at the reporting date for which the Group has not provided for impairment loss. The Group does not hold any collateral over the balances. In respect of trade and bill receivables, individual credit evaluations are performed on all customers requiring credit over a certain amount. These evaluations focus on the customers past history of making payments when due and current liability to pay, and take into account information specific to the customer as well as pertaining to the economic environment in which the customers operate. 76% (2010: 98%) of the trade and bill receivables that are neither past due nor impaired have good settlement history under the Groups individual credit evaluations. The Group does not hold any collateral over these balances.Ageing of trade receivables which are past due but not impaired20112010RMB000RMB000Within one year38,1932,723More than one year but less than two years1,3431,817More than two years but less than three years148212More than three years-12Total39,6844,764Receivables that were past due but not impaired relate to a number of independent customers that have a good track record with the Group. Based on past experience, management believes that no impairment allowance is necessary in respect of these balances as there has not been a significant change in credit quality and the balances are still considered fully recoverable. The Group does not hold any collateral over these balances.Movements in the allowance for doubtful debts of trade receivables20112010RMB000RMB000At 1 January1,9797,603Impairment losses reversed-(691)Impairment losses recognised51,349312Amounts written off as uncollectable-(5,245)At 31 December53,3281,979In determining the recoverability of trade receivables, the Group considers any change in the credit quality of the trade receivables from the date credit was initially granted up to the end of the reporting period. The concentration of credit risk is limited due to the customer base being large and unrelated.Included in the allowance for doubtful debts are individually impaired trade receivables with an aggregate balance of approximately RMB53,328,000 (2010: RMB1,979,000) which in severe financial difficulties. The Group does not hold any collateral over these balances.Movements in the allowance for doubtful debts of other receivables20112010RMB000RMB000At 1 January9,1287,838Impairment losses reversed(216)-Impairment losses recognised 3321,290At 31 December9,2449,128Included in the allowance for doubtful debts are individually impaired other receivables with an aggregate balance of approximately RMB9,244,000 (2010: RMB9,128,000) which in severe financial difficulties. The Group does not hold any collateral over these balances.During the year ended 31 December 2011, the Group recorded compensation income of approximately RMB7,907,000. At the end of the reporting period, the balance had not been settled and included in other receivables in the consolidated statement of financial position. 10. TRADE AND OTHER PAYABLES20112010RMB000RMB000Trade payables355,211326,913Other payables and accrued charges129,908163,389485,119490,302The following is an aged analysis of trade payables presented based on the invoice date at the end of the reporting period. 20112010RMB000RMB000Within one year346,815311,497More than one year but less than two years3,9866,048More than two years but less than three years6013,630Over three years 3,8095,738355,211326,913The average credit period on purchases of goods is approximately 45 days. The Group has financial risk management policies in place to ensure that all payables are settled within the credit timeframe.11. RELATED PARTY TRANSACTIONS(a) Except as disclosed in elsewhere in the consolidated financial statements, the other significant related party transactions, which were carried out in the normal course of the Groups business are as follows:20112010RMB000RMB000SXPGC:- Payment of annual trademark licence fee (note 1)1,1001,100- Rental expense500500Fellow subsidiaries :- Sale of water, electricity, steam and waste materials10,66710,824- Sale of bulk pharmaceuticals and chemical products29,057-- Purchase of raw materials52,69664,408- Design fee income1165 - Impairment losses on amounts due from fellow subsidiaries-12,474Associates :- Sale of water, electricity, steam and waste materials447656- Purchase of raw materials27629Non-controlling interest shareholders :- Sale of bulk pharmaceuticals and chemical raw materials157,367130,031- Purchase of chemical raw materials447838Notes :On 7 December 1996, the Group was granted the exclusive right to use the trademark Xinhua (Trademark) by SXPGC for its existing and future products in and outside the PRC at an initial annual fee of RMB600,000 increasing at the rate of an extra RMB100,000 per year until the annual fee reaches the cap amount of RMB1,100,000, which shall stay as such until the agreement is terminated. The terms of the agreement shall continue to have effect during the validity period of the Trademark, being 28 February 2013, subject to further renewal of the registration of the Trademark. During the year ended 31 December 2011, the annual fee paid by the Group amounting RMB1,100,000 (2010: RMB1,100,000).The Group operates in an economic environment predominated by enterprises directly or indirectly owned or controlled by the PRC government through its numerous authorities, affiliates or other organisations (collectively State-owned Enterprises). During the year ended 31 December 2011, the Group had transactions with State-owned Enterprises including, but not limited to, sales of pharmaceutical products and purchases of raw materials. The directors of the Company consider that transactions with other State-owned Enterprises are activities in the ordinary course of business, and that dealings of the Group have not been significantly controlled or owned by the PRC government. The Group has also established pricing policies for products and such pricing policies do not depend on whether or not the q r s  x z . 0 2 4 T V X ٿ٭lSl77hghm5B*CJOJPJQJ\aJnHphtH1hghmB*CJOJPJQJaJnHphtH%hghmB*CJOJQJaJphhghmCJOJQJaJhghmCJOJQJaJhghm5CJOJQJaJ"hghm5CJOJQJaJo(2jhgh~,5CJOJQJUmHnHo(uhghm5CJOJQJo(+hghm6KHOJPJQJaJnHtHq r t u v  x 2 X rs!"78ij^T^`^ $dT^a$ $UDb]a$$a$X \ ^ ` b  ˭oVoVo;4hghfyB*CJOJPJQJaJnHo(phtH1hghmB*CJOJPJQJaJnHphtH%hghmB*CJOJQJaJphhghmB*OJQJph7hghm5B*CJOJPJQJ\aJnHphtH:hghM\5B*CJOJPJQJ\aJnHo(phtH:hghfy5B*CJOJPJQJ\aJnHo(phtH+hghm5B*CJOJQJ\aJph eopQprsҷҞ҅҅҅jjO@hghmCJOJQJaJ4hgh=NhB*CJOJPJQJaJnHo(phtH4hghB*CJOJPJQJaJnHo(phtH1hghmB*CJOJPJQJaJnHphtH1hghtB*CJOJPJQJaJnHphtH4hghtB*CJOJPJQJaJnHo(phtH%hghmB*CJOJQJaJph4hgh.mNB*CJOJPJQJaJnHo(phtH !"8<FijҿmQ57hghm5B*CJOJPJQJ\aJnHphtH7hghm5B*CJOJPJQJ\aJnHphtH:hgh>H5B*CJOJPJQJ\aJnHo(phtH+hghm5B*CJOJQJ\aJphhghmCJOJQJaJhghmCJOJQJaJ%hghmB*CJOJQJaJph%hghmB*CJOJQJaJph4hgh>HB*CJOJPJQJaJnHo(phtH ѼѓweS?1weShghm6CJ]aJ&hghm6CJPJ]aJnHtH#hghmCJPJaJnHo(tH#hgh.mNCJPJaJnHo(tHhghmCJaJ hghm56CJ\]aJ&hghm5CJPJ\aJnHtH)hgh.mN5CJPJ\aJnHo(tH)hgh5CJPJ\aJnHo(tHhghm5CJ\aJhghmCJKHaJ&hghm5CJPJ]aJnHtHmb $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la$1$IfWDd` $$1$Ifa$ !"#,>?RSZlmƸƠƸƠ|Ơ|ƠƸƠphghgICJaJo($hghgICJKHPJaJnHtH hghgICJPJaJnHtHhghgICJaJhghgICJKHaJhghgI5CJKHaJhghgICJKHaJ#hghgICJPJaJnHo(tHhghmCJKHaJhghm6CJ]aJ$xm $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la$$1$Ifa$gdgI#,5>{mmm$$1$Ifa$gdgI $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la>?SZcl{mmm$$1$Ifa$gdgI $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 lalm{mmm$$1$Ifa$gdgI $$1$Ifa$xkd*$$Ifl,\3 EW! p9!644 laqccc$$1$Ifa$gdgIv$ $Ifa$xkd$$Ifl,\3 EW! p9!644 laooooJ%<TPL HD@< ^TQ ^xkdB$$Ifl,\3 EW! p9!644 laθnP2:hgh*O5B*CJOJPJQJ\aJnHo(phtH:hghs5B*CJOJPJQJ\aJnHo(phtH+hghm5B*CJOJQJ\aJph:hghi5B*CJOJPJQJ\aJnHo(phtH+hgh]4fCJOJPJQJaJnHo(tH+hghmCJOJPJQJaJnHo(tH(hghmCJOJPJQJaJnHtH7hghm5B*CJOJPJQJ\aJnHphtH'-5<D;$1$IfWD`; $$1$Ifa$%<TPL HD@< ^.<TPL HD@< WD^`gd`)F &')+,ɵrZI>,#hghgICJPJaJnHo(tHhghmCJaJ hghm56CJ\]aJ/hghm56CJPJ\]aJnHo(tH)hghgI5CJPJ\aJnHo(tH)hghi5CJPJ\aJnHo(tHhghm5CJ\aJhghmCJaJ&hghm5CJPJ]aJnHtH1hghmB*CJOJPJQJaJnHphtH:hghm5B*CJOJPJQJ\aJnHo(phtH,-4589;<CEQR\qr  *+ȶޢӗ~q~q~qfTf~q#hghgICJPJaJnHo(tHhghgICJaJhghgICJKHaJhghgI5CJKHaJhghgICJaJhghgICJaJ&hghm6CJPJ]aJnHtH#hghgICJPJaJnHo(tHhghmCJaJhghmCJaJhghm6CJ]aJ&hghm5CJPJ\aJnHtHDER\gq~ppp$$1$Ifa$gdA$1$Ifxkd$$Ifl,\S "b :::"644 la]qr~ppp$$1$Ifa$gdA$1$IfxkdF$$Ifl,\S "b :::"644 la]~ppp$$1$Ifa$gdA$1$Ifxkd$$Ifl,\S "b :::"644 la] *~ppp$$1$Ifa$gdA$1$IfxkdB$$Ifl,\S "b :::"644 la]*+,klaYPP^gd`)F & Fgds%<TPL HD@< ^xkd$$Ifl,\S "b :::"644 la]+,6jklmȲvX@v,'hgh=5CJKHPJaJnHtH.hghO(p5B*CJOJQJ\aJo(ph:hghT5B*CJOJPJQJ\aJnHo(phtH:hgh`)F5B*CJOJPJQJ\aJnHo(phtH:hghm5B*CJOJPJQJ\aJnHo(phtH+hghm5B*CJOJQJ\aJph:hgh>H5B*CJOJPJQJ\aJnHo(phtH1hghmB*CJOJPJQJaJnHphtH  $$Ifa$gd*$$1$Ifa$gd=$$1$Ifa$gd* $$1$Ifa$%<TPL HD@< ^ ٫yeWeCeyeW6hgh=CJKHaJ'hgh(:CJKHPJaJnHo(tHhgh=6CJ]aJ'hgh=CJKHPJaJnHo(tH'hgh'CJKHPJaJnHo(tHhgh=CJKHaJ hgh=56CJ\]aJ,hgh=56CJPJ\]aJnHtH-hgh'5CJKHPJ\aJnHo(tH-hgh=5CJKHPJ\aJnHo(tHhgh=5CJKH\aJ*pbVHHH$$1$Ifa$gdA $$Ifa$gdA$$1$Ifa$gdykd>$$Ifl4r&*p#tG?644 laf4*+<Jpq)*W\v|()ʽʽʽآʽآؕʽʽkU*hgh;.5CJKHPJaJnHo(tH*hgh(:5CJKHPJaJnHo(tH'hgh(:5CJKHPJaJnHtHhgh;.CJKHaJhgh;.CJKHaJo(hgh;.CJKHaJhgh;.CJKHaJhgh;.5CJKHaJ$hgh;.CJKHPJaJnHtH'hgh;.CJKHPJaJnHo(tH!*+<JYapseYYYY $$Ifa$gdA$$1$Ifa$gdykd$$Iflr&*p#tG?644 lapqseYKKK$$1$Ifa$gdA $$Ifa$gdA$$1$Ifa$gdykd$$Iflr&*p#tG?644 la)seYKYK$$1$Ifa$gdA $$Ifa$gdA$$1$Ifa$gdVkd]$$Iflr&*p#tG?644 la)*|seYKYK$$1$Ifa$gdA $$Ifa$gdA$$1$Ifa$gdVkd $$Iflr&*p#tG?644 laseWWKW $$Ifa$gdA$$1$Ifa$gdA$$1$Ifa$gdykd $$Iflvr&*p#tG?644 la*.EIseWKW=$$1$Ifa$gd(: $$Ifa$gd(:$$4$Ifa$gd(:$$1$Ifa$gd3kdv $$Iflvr&*p#tG?644 la).BDHIֵ֢naSF9hghoCJKHaJhghoCJKHaJhgho5CJKHaJhghoCJKHaJ$hghoCJKHPJaJnHtHhgh(:CJKHaJ'hgh+ZCJKHPJaJnHo(tH$hgh(:CJKHPJaJnHtHhgh(:CJKHaJ'hgh;.CJKHPJaJnHo(tH'hgh(:CJKHPJaJnHo(tH*hgh(:5CJKHPJaJnHo(tHIxK=$$1$Ifa$gdykd) $$Iflvr&*p#tG?644 la $$Ifa$gd(:$$4$Ifa$gd(:$$1$Ifa$gd3YK$$1$Ifa$gdykd $$Iflr&*p#tG?644 la$$1$Ifa$gdA $$Ifa$gdA%&CJUZarïТ돁ТТcE:hghC5B*CJOJPJQJ\aJnHo(phtH:hghU95B*CJOJPJQJ\aJnHo(phtHhghoCJKHaJo($hghoCJKHPJaJnHtHhghoCJKHaJ'hghoCJKHPJaJnHo(tHhghbCJKHaJhghoCJKHaJhgho5CJKHaJ'hghoCJKHPJaJnHo(tH%&argYKK$$1$Ifa$gdA$$1$Ifa$gdykd $$Iflr&*p#tG?644 la $$Ifa$gdAseWWKW $$Ifa$gdA$$1$Ifa$gdA$$1$Ifa$gdykdB$$Iflr&*p#tG?644 lasj]P]B$$1$Ifa$gd=!w ^`gd{kA ^`gdU9^gdU9kd$$Iflr&*p#tG?644 la  ʶ{d{SF2'hghoCJKHPJaJnHo(tHhgh44CJKHaJ hgh4456CJ\]aJ-hgho5CJKHPJ\aJnHo(tH-hgh445CJKHPJ\aJnHo(tHhgh445CJKH\aJ'hgh44CJKHOJQJ^JaJo('hgh!f05CJKHPJaJnHtH:hghU95B*CJOJPJQJ\aJnHo(phtH.hgh{kA5B*CJOJQJ\aJo(ph  ;@DEGkd$$Ifr$<$4 ap2 $$Ifa$gd44$$1$Ifa$gd44;>?@CDE^cuvмЩ{h{hTF{hhghVMCJKHaJo('hghVMCJKHPJaJnHo(tH$hghVMCJKHOJQJ^JaJhghVMCJKHaJhghVM5CJKHaJ$hghVMCJKHPJaJnHtH$hgh44CJKHOJQJ^JaJ'hghoCJKHPJaJnHo(tHhgh44CJKHaJhgh446CJ]aJ'hgh44CJKHPJaJnHo(tHE^chpuv<kd$$Ifr$<$4 ap2$$1$Ifa$gdA $$Ifa$gdA $1$Ifgd=!wv<kd$$Ifr$<$4 ap2 $$Ifa$gdA$$1$Ifa$gdA $1$Ifgd=!w<kdr$$Ifr$<$4 ap2 $$Ifa$gdA$$1$Ifa$gdA $1$Ifgd=!w.0246@JZblnz| .6NZ\ö|iUöi'hghMbCJKHPJaJnHo(tH$hghMbCJKHOJQJ^JaJ'hghMbCJKHPJaJnHo(tHhghMbCJKHQJaJo(+hghMbCJKHPJQJaJnHo(tHhghMbCJKHaJhghMb5CJKHaJhghMbCJKHaJhghMbCJKHQJaJ$hghMbCJKHPJaJnHtH6@J|:kdb$$Ifr$<$4 ap2$$4$Ifa$gda$$1$Ifa$gdA $1$Ifgd=!w PZ\:kdR$$Ifr$<$4 ap2$$4$Ifa$gda$$1$Ifa$gdA $1$Ifgd=!w\̿~jT>j+$hgh44CJKHPJaJnHtH*hgh445CJKHPJaJnHo(tH*hghVM5CJKHPJaJnHo(tH'hgh445CJKHPJaJnHtH3hgh44CJKHOJPJQJ^JaJnHo(tH'hgh!f05CJKHPJaJnHtH$hghVMCJKHOJQJ^JaJhghVMCJKHaJhghVM5CJKHaJ$hghVMCJKHOJQJ^JaJ$hghVMCJKHPJaJnHtH \<kdB$$Ifr$<$4 ap2 $$Ifa$gdA$$1$Ifa$gdA $1$Ifgd=!w+04cz~$$1$Ifa$gd44 $$Ifa$gd44$$4$Ifa$gd44$$1$Ifa$gd=!w )*-/034xyz}~ƲƑƲƑ~jWjWIWjW;hgha1C5CJKHaJhgha1CCJKHaJo($hgha1CCJKHPJaJnHtH'hgha1CCJKHPJaJnHo(tH$hgh44CJKHOJQJ^JaJhgh44CJKHaJ'hgh44CJKHPJaJnHo(tH'hghVMCJKHPJaJnHo(tH$hgh44CJKHPJaJnHtH'hghCCJKHPJaJnHo(tH$hghCCJKHPJaJnHtH~aVHHHH$$1$Ifa$gdA $1$Ifgd=!wkd2$$Ifr$<$4 ap2 Ҿ󝏝nXB+hghm5B*CJOJQJ\aJph+hghB\CJOJPJQJaJnHo(tH$hgha1CCJKHPJaJnHtHhgh$CJKHaJo(hgh{kACJKHaJo($hgh{kACJKHPJaJnHtHhgha1C5CJKHaJ'hgha1CCJKHPJaJnHo(tHhgh{kACJKHaJo($hgha1CCJKHOJQJ^JaJhgha1CCJKHaJaVHH9H$$1$4$Ifa$gd-(M$$1$Ifa$gdA $1$Ifgd=!wkd$$Ifr$<$4 ap2a__R0"6TPL HD@<%^T^`kd$$Ifr$<$4 ap2wcQ?#hgh0{CJPJQJnHo(tH"hghm5CJPJnHo(tH&hgh0{5CJPJQJnHo(tH&hghd5CJPJQJnHo(tH&hghm5CJPJQJnHo(tH#hghmCJPJQJnHo(tHhghaoCJPJnHo(tHhghmCJPJnHo(tHhghmCJPJnHtHhghmCJ,hghmB*OJPJQJnHo(phtH`kd$$If4FLt%u<d&    4 ahf4 $$Ifa$ İzzhVF=hghmCJhghmCJPJnHo(tH#hgh0{CJPJQJnHo(tH#hghdCJPJQJnHo(tH#hghCJPJQJnHo(tH#hghmCJPJQJnHo(tH"hghm5CJPJnHo(tH&hgh0{5CJPJQJnHo(tH&hghd5CJPJQJnHo(tH&hghm5CJPJQJnHo(tH&hgh5CJPJQJnHo(tH.?PxrffXX$$1$Ifa$gd% $$Ifa$gd%$Ifkd$$If4rLt%ud&4 ahf4.?PQxyϷϷqaSFSFhgh%CJKHaJhgh%5CJKHaJhgh%CJPJnHo(tH#hgh%CJPJQJnHo(tHhghmCJhghmCJPJnHo(tH#hghmCJPJQJnHo(tHhghGJuCJhghGJuCJKHaJhghGJuCJaJhghGJu5CJKHaJhghGJuCJPJnHo(tH#hghGJuCJPJQJnHo(tHPQy{uii[[$$1$Ifa$gd% $$Ifa$gd%$Ifkd($$IfrLt%ud&4 ah{u=u1 $$Ifa$gdA7kdf$$IfL%d&d&4 ah$Ifkd$$IfrLt%ud&4 ahMOaqmg[ $$Ifa$gdA$Ifkd$$IfrLt%ud&4 ah$$1$Ifa$gdA LMOaq  -<=CDFSUij ǺǺǺǺǺǺǺǺǺǺq+hghu6CJOJPJQJaJnHo(tH1hghmB*CJOJPJQJaJnHphtH%hghmB*OJQJnHphtH hgh%hgh%CJKHaJhgh%5CJKHaJhgh%CJPJnHo(tH#hgh%CJPJQJnHo(tHhgh%CJ'{ui[[[$$1$Ifa$gdA $$Ifa$gdA$Ifkdb$$IfrLt%ud&4 ah -<{ui[[[$$1$Ifa$gdA $$Ifa$gdA$Ifkd$$IfrLt%ud&4 ah<=DFSUi{ui[[[$$1$Ifa$gdA $$Ifa$gdA$Ifkd$$IfrLt%ud&4 ahij{ugggg$$1$Ifa$gdA$Ifkd?$$IfrLt%ud&4 ah!"3 4 %!&!{WUUPPPUgd{kA#9TPL HD@<%^kd$$IfrLt%ud&4 ah  !"/7<Zcg   ( 1 3 7 < y z !!!#!%!&!5!齭shghmCJOJQJaJ+hgh^"CJOJPJQJaJnHo(tH(hgh{kACJOJPJQJaJnHtHhgh{kACJOJQJaJo(+hgh{kACJOJPJQJaJnHo(tH+hghmCJOJPJQJaJnHo(tH+hgha.CJOJPJQJaJnHo(tH(&!4!5!-#.#Y#Z#7$8$$$%%&&N(O(**+^gd**TPL HD@<^gd-/^gd-/$^`a$gdEN2^^gd 5!C!Q!!!!!!!!!!!!!!+"4""춛gL1gg4hgh$`eB*CJOJPJQJaJnHo(phtH4hghmB*CJOJPJQJaJnHo(phtH1hghmB*CJOJPJQJaJnHphtH4hgh0<B*CJOJPJQJaJnHo(phtH4hgh B*CJOJPJQJaJnHo(phtH4hghdB*CJOJPJQJaJnHo(phtH4hghdG;B*CJOJPJQJaJnHo(phtH%hghmB*CJOJQJaJph"""""""""##+#,#-#.#ʷrr_Dr.+hghmCJOJPJQJaJnHo(tH4hghI,B*CJOJPJQJaJnHo(phtH$hgh B*PJnHo(phtH4hgh B*CJOJPJQJaJnHo(phtH(hgh B*CJOJQJaJo(ph(hgh?.B*CJOJQJaJo(ph%hghmB*CJOJQJaJph4hgh$`eB*CJOJPJQJaJnHo(phtH4hghdB*CJOJPJQJaJnHo(phtH.#Z#6$8$E$N$X$\$f$n$$$$$$$$ůw\Aw4hghKnB*CJOJPJQJaJnHo(phtH4hgh-/B*CJOJPJQJaJnHo(phtH%hgh-/B*CJOJQJaJph+hghEN2CJOJPJQJaJnHo(tHhghEN2CJOJQJaJ+hgho*CJOJPJQJaJnHo(tH1hghmB*CJOJPJQJaJnHphtH%hghmB*CJOJQJaJphhghmCJOJQJaJ$$$$$$$%%%%%%%%!%@%C%V%Y%Z%]%a%b%%%%%%%%%%%Űذذذ؛؛؀e؀؀4hgh?jB*CJOJPJQJaJnHo(phtH4hgh-/B*CJOJPJQJaJnHo(phtH(hgh?jB*CJOJQJaJo(ph(hgh`LB*CJOJQJaJo(ph%hgh`LB*CJOJQJaJph%hgh-/B*CJOJQJaJph(hgh-/B*CJOJQJaJo(ph!%%% &&&&&&!&$&5&8&9&<&@&A&]&a&r&t&u&v&y&&&&&&&&'нннннrWrW4hgh*B*CJOJPJQJaJnHo(phtH(hgh*B*CJOJQJaJo(ph4hgh`B*CJOJPJQJaJnHo(phtH4hgh-/B*CJOJPJQJaJnHo(phtH%hgh-/B*CJOJQJaJph(hgh-/B*CJOJQJaJo(ph4hghthB*CJOJPJQJaJnHo(phtH''"'&'''B'C'D'E'I'\'_'`'c'g'i'k'''''''''''''''''''''%(0(ӸӈӝӝӈӝӝӈӝӈӸӝӸs(hgh*B*CJOJQJaJo(ph(hgh-/B*CJOJQJaJo(ph4hghVXB*CJOJPJQJaJnHo(phtH4hgh-/B*CJOJPJQJaJnHo(phtH%hgh-/B*CJOJQJaJph1hgh-/B*CJOJPJQJaJnHphtH&0(1(L(((((((((((((((((((((()")#)$)')ʷʜʜpʜ[(hgh-/B*CJOJQJaJo(ph%hghNB*CJOJQJaJph1hgh-/B*CJOJPJQJaJnHphtH4hghmrB*CJOJPJQJaJnHo(phtH%hgh-/B*CJOJQJaJph4hgh-/B*CJOJPJQJaJnHo(phtH4hgh*B*CJOJPJQJaJnHo(phtH')()+)/)v))))))))))** *ѶooT?To**(hgh-/B*CJOJQJaJo(ph(hgh*B*CJOJQJaJo(ph4hgh4B*CJOJPJQJaJnHo(phtH1hgh-/B*CJOJPJQJaJnHphtH4hgh-/B*CJOJPJQJaJnHo(phtH%hgh-/B*CJOJQJaJph4hgh=B*CJOJPJQJaJnHo(phtH4hghmrB*CJOJPJQJaJnHo(phtH%hghmrB*CJOJQJaJph *****:*F*H*J*K*O*S***************++#+Ӿww^w^w^ww^w^w^Iw(hgh*B*CJOJQJaJo(ph1hgh*B*CJOJPJQJaJnHphtH4hgh*B*CJOJPJQJaJnHo(phtH%hgh*B*CJOJQJaJph1hghmB*CJOJPJQJaJnHphtH(hgh-/B*CJOJQJaJo(ph1hgh-/B*CJOJPJQJaJnHphtH%hgh-/B*CJOJQJaJph#+'+3+9+F+G+I+L+T+`++++++++++, , ,,,,,,[,],^,_,u,v,츣Ӹ죸ӔmW+hghmCJOJPJQJaJnHo(tH"hghm5CJOJQJ\aJ(hghmCJOJPJQJaJnHtHhghmCJOJQJaJ(hgh*B*CJOJQJaJo(ph4hgh*B*CJOJPJQJaJnHo(phtH1hgh*B*CJOJPJQJaJnHphtH%hgh*B*CJOJQJaJph ++],_,u,v,--\.].//617122u2v23333"4#4G7H7^ ^`gd-}^gd*v,,,,,,,,,,,,,,;-B---------ѶggLL4hgh1I B*CJOJPJQJaJnHo(phtH4hghT%B*CJOJPJQJaJnHo(phtH4hghBpB*CJOJPJQJaJnHo(phtH1hghmB*CJOJPJQJaJnHphtH4hghSoB*CJOJPJQJaJnHo(phtH4hgh^@B*CJOJPJQJaJnHo(phtH%hghmB*CJOJQJaJph-----.J.n......//// / /// /;/ʷʷpUUU垷pU4hghRB*CJOJPJQJaJnHo(phtH4hgh^@B*CJOJPJQJaJnHo(phtH%hgh-/B*CJOJQJaJph1hghmB*CJOJPJQJaJnHphtH%hghmB*CJOJQJaJph4hghBpB*CJOJPJQJaJnHo(phtH4hghmB*CJOJPJQJaJnHo(phtH;/H/e/h/i/l////////////ҷҷҞҷҷ҃hM24hgh+B*CJOJPJQJaJnHo(phtH4hgh0B*CJOJPJQJaJnHo(phtH4hghyBB*CJOJPJQJaJnHo(phtH4hghmB*CJOJPJQJaJnHo(phtH1hghmB*CJOJPJQJaJnHphtH4hghRB*CJOJPJQJaJnHo(phtH%hghmB*CJOJQJaJph4hgh(B*CJOJPJQJaJnHo(phtH/,00060?0x0000000ʯʯy^C(C4hgh`B*CJOJPJQJaJnHo(phtH4hghla4B*CJOJPJQJaJnHo(phtH4hgh}uPB*CJOJPJQJaJnHo(phtH4hghQs_B*CJOJPJQJaJnHo(phtH4hghbhUB*CJOJPJQJaJnHo(phtH4hghpHB*CJOJPJQJaJnHo(phtH4hgh:R@B*CJOJPJQJaJnHo(phtH4hgh-%B*CJOJPJQJaJnHo(phtH 000000 1 1314151611寖{`E2%hghmB*CJOJQJaJph4hghyBB*CJOJPJQJaJnHo(phtH4hghcKB*CJOJPJQJaJnHo(phtH4hgh}uPB*CJOJPJQJaJnHo(phtH1hgh]LXB*CJOJPJQJaJnHphtH4hgh]LXB*CJOJPJQJaJnHo(phtH4hghla4B*CJOJPJQJaJnHo(phtH4hghCOB*CJOJPJQJaJnHo(phtH 1222272G2u2222222222222222233333ӸӂmӝRӂӝӝ4hghn>x>}>>>G?t???????????+BABBBBBBؽؽؽؽؽؽؽ4hgh/B*CJOJPJQJaJnHo(phtH4hghyB*CJOJPJQJaJnHo(phtH%hghyB*CJOJQJaJph(hghyB*CJOJQJaJo(ph8BDDDEEEEEEEE*G+G,G/G0GmGoG9H:HiHkHIIIISJUJXJoJJJJJKKѶѶy^^^^^^y^yy4hghyB*CJOJPJQJaJnHo(phtH(hghyB*CJOJQJaJo(ph%hghyB*CJOJQJaJph(hgh0FB*CJOJQJaJo(ph4hgh/B*CJOJPJQJaJnHo(phtH4hgh0FB*CJOJPJQJaJnHo(phtH%hgh0FB*CJOJQJaJph$UJJJLLLLMMMMOOOOEPFPdReRQTRT`UaUUUW Wgdgd^gd^gdyKKKLLLLMMMMMMNNNNOOOOOOPPDPFPcReRSSPTRT_UaUnUqUUUwa+hghCJOJPJQJaJnHo(tHhghCJOJQJaJ4hghB*CJOJPJQJaJnHo(phtH4hgh6XAB*CJOJPJQJaJnHo(phtH4hghyB*CJOJPJQJaJnHo(phtH(hghyB*CJOJQJaJo(ph%hghyB*CJOJQJaJph&UUUQViVvVVW WX!XTXUXjXkXYY+Y.YeYhYYYYYp[r[[ \v\w\z\\\\\\\]]]i`j`k``켡ss4hgh$B*CJOJPJQJaJnHo(phtH%hgh$B*CJOJQJaJph4hgh]P&B*CJOJPJQJaJnHo(phtH4hghyB*CJOJPJQJaJnHo(phtH(hghyB*CJOJQJaJo(ph%hghyB*CJOJQJaJph, W X!XYYYYq[r[v\w\\\]]j`k`bbddeeee ^` +gdygd>^gd$^gdy```````b bbbddddeeeeպեեՏjR?%hghmB*CJOJQJaJph.hghm5CJOJPJQJ\aJnHtH+hghyCJOJPJQJaJnHo(tHhghmCJOJQJaJ+hghW8CJOJPJQJaJnHo(tH(hgh$B*CJOJQJaJo(ph4j}hgh$B*CJOJQJUaJph%hgh$B*CJOJQJaJph.jhgh$B*CJOJQJUaJphe'eeeeefffffVfWfXfYfnfofpfqfrfufyf{f|ffffffӸӝӸӂj[ӸhghmCJOJQJaJ.hghm5CJOJPJQJ\aJnHtH4hghmB*CJOJPJQJaJnHo(phtH4hghW8B*CJOJPJQJaJnHo(phtH4hghdB*CJOJPJQJaJnHo(phtH%hghmB*CJOJQJaJph1hghmB*CJOJPJQJaJnHphtHeee{f|fffggggh h!h&h+h4h$V$If^V`a$$V$If^V`a$gd!I$T^T`a$gdC$ T^`a$gde1T^T` ^`^fg g gg"gIgJgTgVgZg[g^ggggʱʖjOjO<%hgh%B*CJOJQJaJph4hgh%B*CJOJPJQJaJnHo(phtH1hghmB*CJOJPJQJaJnHphtH%hghmB*CJOJQJaJph4hghD B*CJOJPJQJaJnHo(phtH1hghvbB*CJOJPJQJaJnHphtH4hghvbB*CJOJPJQJaJnHo(phtH4hghx8B*CJOJPJQJaJnHo(phtHgggghhhh h!h%h&h(h)hj\N@+)hghd5CJPJ\aJnHo(tHhghm5CJ\aJhghmPJnHo(tHhgh!IPJnHo(tH(hghmCJOJPJQJaJnHtH+hghCJOJPJQJaJnHo(tH1hghL/5CJOJPJQJ\aJnHo(tH"hghm5CJOJQJ\aJ1hghm5CJOJPJQJ\aJnHo(tHhghmCJOJQJaJ.hghm5CJOJPJQJ\aJnHtH)h*h+h,h3h4h6h8h9h:hAhBhChhhxdxSH2*hghm5+hghm5B*CJOJQJ\aJphhghmnHtH hghmCJPJaJnHtH&hghm6CJPJ]aJnHtHhghm6CJ]aJ#hghW8CJPJaJnHo(tHhghmCJaJhghm5nHtH hghm56CJ\]aJ)hghm56CJPJ]aJnHtH)hghm5CJPJ\aJnHo(tH)hghW85CJPJ\aJnHo(tH4h:hBhChbhhhheePP$V$If^V`a$&6TPL HD@<{$If^]kd=$$IflF! $  !    4 la $V$If^V`a$hhhhhrr$$1$Ifa$gdP v${$IfVDFWDj^`a$gdM]kd$$IflF! $  !    4 la hhhhhhhhhhhhii i!i"iJiPiViWikiɵ𩛐|fQJ|7fQJ|$hghCJKHPJaJnHtH hgh(hghCJOJPJQJaJnHtH+hgh5CJOJPJQJaJnHtHhghCJKHaJ hghw\hghw\CJaJhghw\5CJaJo(hghw\5CJaJ'hghCJKHPJaJnHo(tH'hghw\CJKHPJaJnHo(tH$hghw\CJKHPJaJnHtHhghw\aJ hghmhhii iyy$d$Ifa$gdPVi$IfVD$WD2^V`igdM]kd1 $$IflF! $  !    4 la  i!iJiPiViyy$d$Ifa$gdP.$IfVDPWD^`.gdM]kd $$IflF! $  !    4 la ViWikioiqiyy$d$Ifa$gdPVi$IfVD$WD2^V`igdM]kd1!$$IflF! $  !    4 la kioiqiriiiiiiiiiiiiiiiiiijj j jͯ̓sbNG hgh}&hgh}hCJOJQJ^JaJ!hgh}h5CJKHaJhgh}5CJKHaJo(hgh}5CJKHaJhghCJaJo(#hghCJPJaJnHo(tH hghCJPJaJnHtHhghCJKHaJ hgh(hghCJOJPJQJaJnHtH+hgh5CJOJPJQJaJnHtHqiriiiiyy$d$Ifa$gdPVi$IfVD$WD2^V`igdM]kd!$$IflF! $  !    4 la iiiii||$d$Ifa$gdP&d$IfWD^&`gdM]kd1"$$IflF! $  !    4 la iij j jww$d$If]a$gdP$d$If]^a$gd~]kd"$$IflF! $  !    4 la  j jDjKjMjyf$d$If]a$gdP$d$Ifa$gdP.$IfVDPWD^`.gd}]kd1#$$IflF! $  !    4 la  j j6jCjDjJjKjLjMjNj^j_j`jaj{j|jȰqjZJ7j)hgh}CJKHaJo($hgh}OJPJQJaJnHtHhgh}5CJOJQJaJhgh}5CJKH\aJ hgh}&hgh}hCJOJQJ^JaJ#hgh}CJOJQJ^JaJo(1hgh}h5CJOJPJQJaJnHtH.hgh}5CJOJPJQJaJnHo(tHhgh}hCJKHaJhghCJKHaJo(hgh}CJKHaJhgh)9CJKHaJMjNj^j_j`jq$d$Ifa$gdP$d$Ifa$gdPV$If^V`]kd#$$IflF! $  !    4 la `jaj|jjjyy$d$Ifa$gdPVi$IfVD$WD2^V`igdU]kd1$$$IflF! $  !    4 la |jjjjjjjjjjjjjjjkkkk=kBk[k\k`kdkekfk͎xi`N#hghm5B*OJQJ\phhgh}aJhgh}KHOJQJaJ*hgh}5CJKHPJ\aJnHtHhgh}5CJKH\aJ'hgh}CJKHPJaJnHo(tHhgh}CJKHaJo(hgh}CJKHaJ hgh}(hgh}CJOJPJQJaJnHtH+hgh}5CJOJPJQJaJnHtHjjjjj{{$d$Ifa$gdPVi$IfVD$WD2^V`igd_kd$$$IflF! $  !    4 la jjjjjq$d$Ifa$gdP$d$Ifa$gdPV$If^V`]kd5%$$IflF! $  !    4 la jjkkk||$d$Ifa$gdP$IfVDIWDj^`]kd%$$IflF! $  !    4 la kk\k`kdk||$d$Ifa$gdP$IfVDIWDj^`]kd5&$$IflF! $  !    4 la dkekkkmm mmOnPnUo|zqaa_qqq$d^`a$^gd _%6TPL HD@<{d<^]kd&$$IflF! $  !    4 la  fkkkkkkkkkk@l_llllllllllllmmmmɶmmT1hghzg5CJOJPJQJ\aJnHo(tH1hgh _B*CJOJPJQJaJnHphtH4hgh _B*CJOJPJQJaJnHo(phtH(hgh _B*CJOJQJaJo(ph%hgh _B*CJOJQJaJphhghmOJQJ%hghmB*CJOJQJaJph/hghm5B*OJPJQJ\nHphtHmm;m?mmmmmmmnnn@nnn oooooo o'o(o>o@oQoSoUoVo~oުޕޕޕzޕުުުުb.hghm5CJOJPJQJ\aJnHtH4hghHB*CJOJPJQJaJnHo(phtH(hgh _B*CJOJQJaJo(ph1hgh _B*CJOJPJQJaJnHphtH4hgh _B*CJOJPJQJaJnHo(phtH%hgh _B*CJOJQJaJphhghmCJOJQJaJUoVo}o~opp_q`qqqssssxxx'y(y=y>yZy[ymy˸mU?U+hgh5CJOJPJQJaJnHtH.hgh5CJOJPJQJaJnHo(tH4hghm5;CJOJPJQJ\aJnHo(tH(hghB*CJOJQJaJo(ph4hghB*CJOJPJQJaJnHo(phtH%hghB*CJOJQJaJphhghmCJOJQJaJ hghm@CJOJQJaJ(hghmCJOJPJQJaJnHtH3wJwKwxx=y>yyyyyy$$1$Ifa$gdT T^$^a$gdk$a$gdk ^`^gdd my}y~yyyyyyyyyи|fR>*'hghXCJKHPJaJnHo(tH'hgh<_2CJKHOJQJ\^JaJ&hgh<_25CJKHOJQJaJo(+hghmCJOJPJQJaJnHo(tH+hgh,CJOJPJQJaJnHo(tH+hghCJOJPJQJaJnHo(tHhghm5CJOJQJaJ.hghe5CJOJPJQJaJnHo(tH.hghX5CJOJPJQJaJnHo(tH.hgh M5CJOJPJQJaJnHo(tH yyyyyyyyyyyyy뱦t^H2*hghJ05CJKHPJaJnHo(tH*hgha5CJKHPJaJnHo(tH*hgh<_25CJKHPJ\aJnHtHhghX5CJKH\aJhghX5CJKHaJ'hgh<_2CJKHOJQJ\^JaJhgh<_2CJKHhgh<_2CJKH\aJo('hghXCJKHPJaJnHo(tH*hgh<_2CJKHPJ\aJnHo(tH'hgheCJKHPJaJnHo(tH yyyyyyy|nnnn$$1$Ifa$gdT $1$IfgdTwkd5'$$Ifl4TF #& &J& #6    44 lagpyyyyyyyyyyyyyz9z뿲wdYF8*hgheCJKH\aJhghe5CJKHaJ$hgheCJKHPJaJnHtHhgh<_2CJKH$hghXCJKHPJaJnHtH'hghJ0CJKHPJaJnHo(tH$hghJ0CJKHPJaJnHtH'hgh<_2CJKHPJ\aJnHtHhghXCJKHaJ*hgh<_25CJKHPJ\aJnHtH*hghJ05CJKHPJaJnHo(tH'hghX5CJKHPJaJnHtHyyyzz(z9zWL>>>>$$1$Ifa$gdp $1$IfgdTkd(($$Ifl4Tr +# &&&&#644 lagp29z:zWzhzyzzzYD6666$$1$Ifa$gdpL$1$IfWD^L`gdTkd1)$$IflTr +#& ''''#644 lagp29z:zWzyzzzzzzz{6{X{Y{t{{{{{{{|!|?|]|^|y||||||||}}5}9}=}>}[}v}}}}}}}~~*~F~c~d~~~~~~~  Թ✹hghe5CJKH\aJhgheCJKHaJhgheCJKH\aJhgheCJKHaJhghe5CJKHaJ$hgheCJKHPJaJnHtHhgheCJKH=zzzzzzzYN@@@@$$1$Ifa$gdp $1$IfgdTkd8*$$IflTr +#& ''''#644 lagp2zz{%{6{G{X{YN@@@@$$1$Ifa$gdp $1$IfgdTkdM+$$IflTr +#& ''''#644 lagp2X{Y{t{{{{{YN@@@@$$1$Ifa$gdp $1$IfgdTkdb,$$IflTr +#& ''''#644 lagp2{{{{{{{YN@@@@$$1$Ifa$gdp $1$IfgdTkdw-$$IflTr +#& ''''#644 lagp2{||!|0|?|YN=//$$1$Ifa$gdp $1$IfWD` gdT $1$IfgdTkd.$$IflTr +#& ''''#644 lagp2?|N|]|^|y|||K6 $1$IfWDp^ `gdTkd/$$IflTr +#& ''''#644 lagp2$$1$Ifa$gdp||||||||K@ $1$IfgdTkd0$$IflTr +#& ''''#644 lagp2$$1$Ifa$gdp|}}5}7}9};}K6 $1$IfWDp^ `gdTkd1$$IflTr +#& ''''#644 lagp2$$1$Ifa$gdp;}=}>}[}h}v}}}K@ $1$IfgdTkd2$$IflXr +#& ''''#644 lagp2$$1$Ifa$gdp}}}}}~~YD6666$$1$Ifa$gdp $1$IfWDp^ `gdTkd3$$IflTr +#& ''''#644 lagp2~~*~8~F~U~c~YN@@@@$$1$Ifa$gdp $1$IfgdTkd 5$$Iflr +# ''''#644 lagp2c~d~~~~~~YD6666$$1$Ifa$gdpD$1$IfWD^`DgdTkd6$$IflTr +#& ''''#644 lagp2~~~~~~ YD6666$$1$Ifa$gdp $1$IfWDp^ `gdTkd47$$IflTr +#& ''''#644 lagp2  DQ^lzYD6666$$1$Ifa$gdp $1$IfWD^` gdTkdI8$$IflXr +#& ''''#644 lagp2 D^z{#$=Yvẁ܀݀,./01OYcdց1MNǂȂ͂ źҬźҬźźҬźźźźźź'hgheCJKHPJaJnHo(tHhgheCJKH\aJhgheCJKHhgheCJKHaJhghe5CJKHaJhgheCJKHaJ$hgheCJKHPJaJnHtH$$IflTr +#& ''''#644 lagp201OTY^cYD6666$$1$Ifa$gdp $1$IfWD^` gdTkd?$$IflTr +#& ''''#644 lagp2cdYD6666$$1$Ifa$gdp $1$IfWD^` gdTkd@$$IflTr +#& ''''#644 lagp2ƁցP;---$$1$Ifa$gdp $1$IfWD^` gdTkdB$$IflTr +#& ''''  #644 lagp2#1B- $1$IfWD^` gdTkd-C$$IflTr +#& ''''  #644 lagp2$$1$Ifa$gdp1?MNB- $1$IfWD^` gdTkdTD$$IflXr +#& ''''  #644 lagp2$$1$Ifa$gdpłǂȂ B- $1$IfWD^` gdTkdmE$$IflXr +#& ''''  #644 lagp2$$1$Ifa$gdp &()*B8 T^kdjF$$IflXr +#& ''''  #644 lagp2$$1$Ifa$gdp ()*,67:;<=>AeëhM8/%hghXCJo(hghXCJ(hghm56CJOJQJ\]aJ4hgh)G5CJOJPJQJ\]aJnHo(tH1hghm5CJOJPJQJ\]aJnHtH-hghm5CJOJQJ\]aJnHtH%hghm5CJOJQJ\]aJ/hghm56OJPJQJ\]nHo(tH+hghmCJOJPJQJaJnHo(tHhgheCJKHhgheCJKHaJhghe5CJKHaJ*,=>ԃՃ89qrzrdgd1t(<TPL HD@<e C^gdrO%<TPL HD@<e C^"7TPL HD@<e C^ $da$gdX T^ esvԃՃ؃89:Q[pqr¬uW9:hghRv5B*CJOJPJQJ\aJnHo(phtH:hghm5B*CJOJPJQJ\aJnHo(phtH=hghqk5;B*CJOJPJQJ\aJnHo(phtH.hghm5;B*CJOJQJ\aJph+hghm5B*CJOJQJ\aJph4hghmB*CJOJPJQJaJnHo(phtHhghXCJPJnHo(tHhghXCJo(hghXCJrӿӡzdzNzN= hgh1tCJPJaJnHtH*hgh1t>*CJOJQJaJnH o(tH +hgh1t>*CJOJPJQJaJnHtHhgh1t>*CJOJQJaJhgh1tCJaJhgh1t5CJaJ:hghrO5B*CJOJPJQJ\aJnHo(phtH'hghrO5B*CJOJQJo(ph3hghrO5B*CJOJPJQJnHo(phtH$hghrO5B*CJOJQJph=pkdG$$Ifl\r#+vvv$4 a%$!d$Ifa$gdT<*%$!d$4$Ifa$gdT<*%$!d$Ifa$gdT<*Zd$If^Z`gdT<*zfWWW$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdH$$Ifl\r#+vvv$4 a%$!d$Ifa$gdT<*zk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdH$$Ifl\r#+vvv$4 aɄ˄Մ߄zk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdH$$Ifl\r#+vvv$4 aɄʄ˄̄̈́ЄфՄބ߄ #*+.01<CEFHJOPQ_mnt}~ɸɸɸɸɸɸɸɸɸɸɸɸɸɕɕɸhgh1tCJaJo(hgh1t5CJaJhgh1tCJaJ hgh1tCJPJaJnHtH#hgh1tCJPJaJnHo(tH#hghCJPJaJnHo(tH#hgh1t5CJPJaJnHtH:߄zkSS$d$&dIfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkd{I$$Ifl\r#+vvv$4 a zk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdI$$Ifl\r#+vvv$4 a #+zk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdwJ$$Ifl\r#+vvv$4 a+,-./0zk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdJ$$Ifl\r#+vvv$4 a01CDJPzk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdsK$$Ifl\r#+vvv$4 aPQ^_fmzk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdK$$Ifl\r#+vvv$4 amn}~zkXX$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdoL$$Ifl\r#+vvv$4 aȅzk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdL$$Ifl\r#+vvv$4 a…Åƅȅ #*-09:<=AFGHIJKLM_`gno{ѳѧѓѧ&hgh1thCJPJaJnHtHhgh1t5CJaJ#hghCJPJaJnHo(tHhgh1tCJaJo(hgh1tCJaJ hgh1tCJPJaJnHtH#hgh1tCJPJaJnHo(tH:ȅɅzk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdkM$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdM$$Ifl\r#+vvv$4 a:;AGzkSS$d$&dIfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdgN$$Ifl\r#+vvv$4 aGHIJKLzk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdN$$Ifl\r#+vvv$4 aLM_`gozk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdcO$$Ifl\r#+vvv$4 aopzkSS$d$&dIfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdO$$Ifl\r#+vvv$4 a†Ȇ܆݆03459>?GIJNUVa{۾۾۾۳۾۾۾۾π۾)hgh1th<CJPJaJnHo(tH#hgh1t5CJPJaJnHtHhgh1t5CJaJhgh1tCJaJ hgh1tCJPJaJnHtHhgh1tCJaJo(#hgh1tCJPJaJnHo(tH#hghCJPJaJnHo(tH1zk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkd_P$$Ifl\r#+vvv$4 a†zkSS$d$&dIfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdP$$Ifl\r#+vvv$4 a†ÆĆņƆdžzk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkd[Q$$Ifl\r#+vvv$4 adžȆzkVV$nd$4$If]na$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdQ$$Ifl\r#+vvv$4 a|m^^$d$Ifa$gdT<*$d$Ifa$gdT<*d$IfVDG^gd1tpkdWR$$Ifl\r#+vvv$4 a239?|mUU$d$&dIfPa$gdT<*$d$Ifa$gdT<*d$IfVDG^gd1tpkdR$$Ifl\r#+vvv$4 a?@ABCDzk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdSS$$Ifl\r#+vvv$4 aDEFGNVzkSS$d$&dIfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdS$$Ifl\r#+vvv$4 aVWXYZ[zk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdOT$$Ifl\r#+vvv$4 a[\]^_`zk\\$d$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdT$$Ifl\r#+vvv$4 a`azkSS#$d$&dIfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdKU$$Ifl\r#+vvv$4 a·χч҇ia\PA$d$Ifa$gdT<* d$IfgdT<*gdDdgdrO%<TPL HD@<e C^pkdU$$Ifl\r#+vvv$4 a·ч҇ԇׇڇ܇އƵxiii]K#hghD5CJPJaJnHtHhghD5CJaJhghDCJOJQJaJhghDCJaJo(*hghD>*CJOJQJaJnH o(tH hghD>*CJOJQJaJhghDCJaJ hghDCJPJaJnHtH"hghrO5CJPJnHo(tHhghrO5CJ:hghrO5B*CJOJPJQJ\aJnHo(phtH҇ӇԇՇևׇ܇thYDD%$!d$4$Ifa$gdT<*$d$Ifa$gdT<* d$IfgdT<*pkdGV$$If\r+BY#$4 a%$!d$4$Ifa$gdT<*oKs^^%$!d$4$Ifa$gdT<*$d$Ifa$gdT<* d$IfgdT<*pkdV$$If\r+BY#$4 axiTT%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*$d$IfWD^`$gdT<*pkdSW$$If\r+BY#$4 axiTT%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*$d$IfWD^`$gdT<*pkdW$$If\r+BY#$4 a'zkMM%$!d$&d4$IfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkd_X$$If\r+BY#$4 a&'*,AKTVYĈڈ]p{|}~ӾӾӾuu\1hghDh^BCJOJPJQJaJnHo(tH#hghDCJPJaJnHo(tH hghDCJPJaJnHtHhghDCJaJo(hghDCJOJQJaJhghDCJaJ(hghDCJOJPJQJaJnHtH+hghDCJOJPJQJaJnHo(tH+hghDCJOJPJQJaJnHo(tH$'()*+,zkVV%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdX$$If\r+BY#$4 a,-STUVzkVV%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdqY$$If\r+BY#$4 aVWzkVV%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*d$If^`gdT<*pkdY$$If\r+BY#$4 axiTT%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*4d$IfWDt^4`gdT<*pkdZ$$If\r+BY#$4 a|}vgRR%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*O[d$IfVDGWD^O`[gdDpkd[$$If\r+BY#$4 aʼnlj҉Ӊ։؉ى !$&'JNOPRʾۄxjxXxۨۄxXxB+hghDCJOJPJQJaJnHo(tH#hghD5CJPJaJnHtHhghD5CJaJo(hghD5CJaJhghDCJOJQJaJ(hghDCJOJPJQJaJnHtH+hghDCJOJPJQJaJnHo(tHhghDCJaJo( hghDCJPJaJnHtHhghDCJaJ1hghDh^BCJOJPJQJaJnHo(tHʼnƉlj͉ӉqbbFF%$!d$&dIfPa$gdT<*$d$Ifa$gdT<*J:d$IfVD7WD^J`:gdDukd[$$If\r+BY#$4 agfӉԉՉ։׉؉zkVV%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkd7\$$If\r+BY#$4 a؉ى!xiMM%$!d$&dIfPa$gdT<*$d$Ifa$gdT<*:d$IfWD^`:gdT<*pkd\$$If\r+BY#$4 a!"#$%&zkVV%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdO]$$If\r+BY#$4 a&'OPW^zkMM%$!d$&d4$IfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkd]$$If\r+BY#$4 aRSW]^acdҊ݊ފ"龳龳龳龳zgM3hghrO5B*CJOJPJQJnHo(phtH$hghrO5B*CJOJQJphhghD5CJ\aJhghD5CJaJhghD5CJOJQJaJhghDCJOJQJaJhghDCJaJ(hghDCJOJPJQJaJnHtH+hghDCJOJPJQJaJnHo(tH+hghDCJOJPJQJaJnHo(tH^_`abczkVV%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdg^$$If\r+BY#$4 acd}E3nd$IfWD2`ngdT<*7kdy_$$Ifr#$$4 a%!d$IfgdT<*pkd^$$If\r+BY#$4 aъҊjXnd$IfWD2`ngdT<*pkd_$$If\r+BY#$4 a%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*Ҋ؊ފߊp\M8%$!d$4$Ifa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkdW`$$If\r+BY#$4 a%$!d$&d4$IfPa$gdT<*yeV88%$!d$&d4$IfPa$gdT<*$d$Ifa$gdT<*Zd$If^Z`gdT<*pkd`$$If\r+BY#$4 a%$!d$4$Ifa$gdT<*#$*^J6%$!d0$Ifa$gdT<*Zd0$If^Z`gdT<*(<TPL HD@<e C^gdrOdgdDpkdoa$$If\r+BY#$4 a"#$*-./134M`DZmUG6 hghSCJPJaJnHtHhghS5CJ\aJ.hghS>*CJOJPJQJaJnH o(tH *hghS>*CJOJQJaJnH o(tH +hghS>*CJOJPJQJaJnHtH.hghS>*CJOJPJQJaJnHo(tH+hghS>*CJOJPJQJaJnHtHhghS>*CJOJQJaJhghSCJaJ:hghrO5B*CJOJPJQJ\aJnHo(phtH*/4567]I:$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkda$$Ifl\[`J," E64 la%$!d0$Ifa$gdT<*%$!xd0$IfUD2]xa$gdS7?GHIJKLgSDD$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdb$$Ifl\[`J," E64 la$d0$Ifa$gdT<*$xd0$IfUD2]xa$gdSLM`abcwhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkd+c$$Ifl\[`J," E64 lacdyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdc$$Ifl\[`J," E64 la‹#$14=>@ABFLMmqrv}~ʌьҌԌՌٌތߌܽѱܱѱܱܱhghSCJaJo(&hghShCJPJaJnHtHhghSCJaJ hghSCJPJaJnHtH#hghSCJPJaJnHo(tHB‹yj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkd[d$$Ifl\[`J," E64 la‹Ëyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdd$$Ifl\[`J," E64 la$yj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkde$$Ifl\[`J," E64 la$%>?FMyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkd#f$$Ifl\[`J," E64 laMNmnv~yj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdf$$Ifl\[`J," E64 la~yj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdSg$$Ifl\[`J," E64 laьҌٌߌyjRR$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdg$$Ifl\[`J," E64 laߌwhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdh$$Ifl\[`J," E64 lawhPP$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdi$$Ifl\[`J," E64 lawhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdi$$Ifl\[`J," E64 lawhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdKj$$Ifl\[`J," E64 la $%)01MOPQTUY`aƍȍɍۍ%&)*.56<>?@ACDGHNQvxĸĦĸĸĸĸĸ#hghmhCJPJaJnHo(tHhghSCJaJo(#hghSCJPJaJnHo(tH hghSCJPJaJnHtHhghSCJaJhghS5CJ\aJ? !)1yj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdj$$Ifl\[`J," E64 la12NOQYayyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkd{k$$Ifl\[`J," E64 laabyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdl$$Ifl\[`J," E64 laƍɍyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdl$$Ifl\[`J," E64 laɍʍڍۍyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdCm$$Ifl\[`J," E64 layj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdm$$Ifl\[`J," E64 la%&.6yjRR$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdsn$$Ifl\[`J," E64 la6789:;whYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkd o$$Ifl\[`J," E64 la;<=>HRpaa$d0$Ifa$gdT<*$d0$Ifa$gdT<* d0$IfgdT<*tkdo$$Ifl\[`J," E64 laRSvwyyjRR$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkd;p$$Ifl\[`J," E64 laxyz{~ҎԎՎ *+,-./279GJST޽̲޲޲޲ށ޲̲̲̲̲́́́޲ hghSCJPJaJnHtH#hghmhCJPJaJnHo(tHhghS5CJ\aJhghSCJaJhghShCJaJo(#hghSCJPJaJnHo(tHhghSCJaJo()hghShCJPJaJnHo(tH2whYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdp$$Ifl\[`J," E64 lawhPP$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdkq$$Ifl\[`J," E64 lawhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdr$$Ifl\[`J," E64 lawhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdr$$Ifl\[`J," E64 laҎՎݎyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkd3s$$Ifl\[`J," E64 layj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkds$$Ifl\[`J," E64 la+,28yj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdct$$Ifl\[`J," E64 la89TUXZyj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdt$$Ifl\[`J," E64 laTXYhqrs}~ˏ̏ΏϏ %&')*.56<bcdefhimַַַַַַ֩֩hghSCJ\aJo(hghS5CJ\aJ hghSCJPJaJnHtHhghSCJaJhghSCJaJo(#hghSCJPJaJnHo(tHBZ[ghlryj[[$d0$Ifa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkdu$$Ifl\[`J," E64 lars~yjRR$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*d0$IfVDG^gdStkd+v$$Ifl\[`J," E64 lawhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdv$$Ifl\[`J," E64 lawhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkd[w$$Ifl\[`J," E64 laˏ̏͏ΏwhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Z4d0$If^Z`4gdT<*tkdw$$Ifl\[`J," E64 laΏϏwhPP$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdx$$Ifl\[`J," E64 lawhYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkd#y$$Ifl\[`J," E64 la whPP$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdy$$Ifl\[`J," E64 la whYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdSz$$Ifl\[`J," E64 la%&.6whPP$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkdz$$Ifl\[`J," E64 la6789:;whYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkd{$$Ifl\[`J," E64 la;<bcmwwhPP$d0$&dIfPa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkd|$$Ifl\[`J," E64 lamvwxyz|}~ÐĐƐǐʐԐՐ123467;Dѷ{{{i{i{i{i{{{{#hgh['CJPJaJnHo(tH#hgh-!CJPJaJnHo(tH hgh-!CJPJaJnHtHhgh-!CJaJhgh-!5CJ\aJhgh-!CJaJo(hghS5CJ\aJhghSCJaJ hghSCJPJaJnHtH#hghSCJPJaJnHo(tH)wxyz{|whYY$d0$Ifa$gdT<*$d0$Ifa$gdT<*Zd0$If^Z`gdT<*tkd|$$Ifl\[`J," E64 la|}~rcTT$d$Ifa$gd~$d$Ifa$gd~Zd$If^Z`gd~gd-!tkdK}$$Ifl\[`J," E64 la{l]]$d$Ifa$gd~$d$Ifa$gd~d$IfVDG^gd-!rkd}$$Ifl\_fJ," F64 laːՐ{l]]$d$Ifa$gd~$d$Ifa$gd~d$IfVDG^gd-!rkdw~$$Ifl\_fJ," F64 laՐ֐{lTT$d$&dIfPa$gd~$d$Ifa$gd~d$IfVDG^gd-!rkd $$Ifl\_fJ," F64 layj[[$d$Ifa$gd~$d$Ifa$gd~Zd$If^Z`gd~rkd$$Ifl\_fJ," F64 la01;Eyj[[$d$Ifa$gd~$d$Ifa$gd~Zd$If^Z`gd~rkd3$$Ifl\_fJ," F64 laDEF`acdhnouґӑԑՑّޑߑ!"#$%'(,345679ҸĩҸҸhgh-!CJOJQJaJhgh-!5CJ\aJo(hgh-!CJaJo(hgh-!5CJ\aJ#hgh-!CJPJaJnHo(tHhgh-!CJaJ hgh-!CJPJaJnHtHABFOPQRSdqruZ@2hgh~(5@CJOJPJQJ\aJnHtH5hgh+5@CJOJPJQJ\aJnHo(tH5hgh~(5@CJOJPJQJ\aJnHo(tH&hgh~(5@CJOJQJ\aJ+hghECJOJPJQJaJnHo(tHhghSCJaJo( hgh-!CJPJaJnHtH#hgh-!CJPJaJnHo(tHhgh-!CJaJo(hgh-!CJaJPQRSvqL<d^`gdrO%<TPL HD@<e C^gd~('$ da$gdEgdStkd$$Ifl?\_fJ," F64 la%&'(01'(01Ը|cH/|/|c|c0hghrOB*CJOJQJaJnHo(phtH4hghrOB*CJOJPJQJaJnHo(phtH1hghrOB*CJOJPJQJaJnHphtH-hghrOB*CJOJQJaJnHphtH+hghrOCJOJPJQJaJnHo(tHhghrO5CJ\aJo(6hghrO5CJKHOJPJQJ\^JaJnHtHhghrO5CJ\aJ:hghrO5B*CJOJPJQJ\aJnHo(phtH12]^lm$d$H$IfVD^a$gdyV$dH$VD^a$gdyV$d^a$gdyVd^`gdrO#9TPL HD@<+{^ UVD^Ugdw~gdrO 1267FUV]^aeҔ—×vjVJhghyV6CJaJ&hghyV6CJPJaJnHo(tHhghz5CJaJo(hghz5CJaJhghyVCJaJo(hghyVCJaJ4hghrOB*CJOJPJQJaJnHo(phtHhghrO5CJ\aJ)hghrO5CJPJ\aJnHo(tHhghrO5CJ\aJo(4hgh[B*CJOJPJQJaJnHo(phtHbcu<Ukd$$Ifl0hh#6 t6"644 la$d$H$IfVD^a$gdyVUkdO$$Ifl0hh#6 t6"644 laƖ1>Skd$$Ifl0hh#6 t6"644 la$d$H$IfVD^a$gdyVUkd$$Ifl0hh#6 t6"644 la12C<UkdS$$Ifl0hh#6 t6"644 la$d$H$IfVD^a$gdyVUkd$$Ifl0hh#6 t6"644 laWX>?ךؚ6d$H$IfVD^gdyV$d$H$IfVD^a$gdyV$d^a$gdyV$dVD,^a$gd[' 7$8$H$gdyV$d^a$gdyV$d7$8$H$^a$gdyV~>?ךؚ4567JKno<=>?\]^_egܜݜޜʹؙؙؙؙؙؙؒؒؒؒؒؒؒ hghyVhghyVCJH*aJnH tH hghyVCJ\aJnH tH hghyVCJPJaJnHtHhghyV6CJaJo(hghyVCJaJhghyVCJaJo(hghyVCJaJnH o(tH 967Kx%Skd$$Ifl0hT,"e t644 la$u:d$IfVD]:^a$gdyV$d$H$IfVD^a$gdyVSkd$$Ifl0hT,"e t644 la>eu:d$IfVD]:^gdyVSkd$$Ifl0hT,"e t644 la:d$IfVD]:^gdyV$d$H$IfVD^a$gdyV>?G^_,SkdG$$Ifl0hT,"e t644 la:d$IfVD]:^gdyV$d$H$IfVD^a$gdyVSkd$$Ifl0hT,"e t644 la_h{Skd$$Ifl0hT,"e t644 lau:d$IfVD]:^gdyV$d$H$IfVD^a$gdyVޜߜ{(Skdp$$Ifl0hT,"e t644 lau:d$IfVD]:^gdyV$d$H$IfVD^a$gdyVSkd$$Ifl0hT,"e t644 laޜߜGHIJ]^"#$%9nopqžÞhghUCJPJnHo(tHhghyVCJhghyVCJH*o(#hghyVCJPJaJnHo(tHhghyVCJH*aJo(hghyVCJH*aJnH tH hghyVCJaJo(hghyVCJaJ hghyV4ߜI{SkdӍ$$Ifl0hT,"e t644 lau:d$IfVD]:^gdyV$d$H$IfVD^a$gdyVIJ^,Skd$$Ifl0hT,"e t644 la:d$IfVD]:^gdyV$d$H$IfVD^a$gdyVSkd6$$Ifl0hT,"e t644 laĝSkd$$Ifl0hT,"e t644 la:d$IfVD]:^gdyV$d$H$IfVD^a$gdyV$%,Skd$$Ifl0hT,"e t644 la:d$IfVD]:^gdyV$d$H$IfVD^a$gdyVSkd_$$Ifl0hT,"e t644 la%9pqSkd%$$Ifl0hT,"e t644 la:d$IfVD]:^gdyV$d$H$IfVD^a$gdyVJӟ_`~ymZ$d7$8$H$^a$gdyV $7$8$H$a$gdyVHdVDWD^H`gdU4$dVDWD^4`$gdyV $da$gdyVSkd$$Ifl0hT,"e t644 la HJKLMҟӟԟ֟\]^`}Ѡ'+YZajʺʺʩʩʩxxxxxxxhghyVCJaJhghyV6CJaJo(hghyV6CJaJhghyVCJaJo( hghyVCJPJaJnHtHhghUCJPJnHo(tHhghyVCJhghyVCJH*PJnHtHhghyVCJH*o(hghyVCJPJnHo(tH/~YZ;<kl89-."$7$8$H$VD^a$gdyV!$ & F d1$7$8$H$^`a$gdyV$d7$8$H$^a$gdyVjk̢͢-.'(%QR$%/ZeLM';<mow{ͪΪԪժتOPjkl&hghyV6CJPJaJnHo(tHhghyV6CJaJo(#hghyVCJPJaJnHo(tHhghyVCJaJhghyVCJaJo(D79s|,-."#(>?HIiϰ %&rӸn]n]n]n]n]n]Rhgh$+CJaJ hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tH4hghpMSB*CJOJPJQJaJnHo(phtHhgh@)5CJ\aJhgh@)5CJ\aJo(4hghrOB*CJOJPJQJaJnHo(phtHhghyVCJaJhghyVCJaJo(hghyVCJhghyV6CJaJ"#>? "\$d$Ifa$gdqW7Vd$IfVD^Vgd$+$d^a$gd$+$d^a$gd$+d^`gd@)#9TPL HD@<+{^˱"#\]`o²òݲ.1<Juvӳ,-NOPQ׿׿׿ˉu&hgh$+>*CJPJaJnH o(tH "hgh$+>*CJaJnH o(tH #hgh$+>*CJPJaJnHtH#hgh$+5CJPJaJnHtHhgh$+CJ]aJhgh$+>*CJaJhgh$+CJaJ hgh$+CJPJaJnHtHhgh$+CJaJo()\]^_`nG2$Vd$IfVD^Va$gd$+Lkd\$$If0p#/ | 4 aS d$IfgdqW7Vd$IfVD^Vgd$+Lkd$$If0p#/ | 4 aSn²߲GLkdD$$If0p#/ | 4 aSVd$IfVD^Vgd$+Lkd͑$$Ifq0p#/ | 4 aS d$IfgdqW708Lkd8$$If0p#/ | 4 aS d$IfgdqW7Vd$IfVD^Vgd$+Lkd$$If0p#/ | 4 aS$d$Ifa$gdqW701uvwӳԳq\\G$\d$VDQ^\`a$gd$+$\#d$VDQ^\`#a$gd$+$RdVDb^Ra$gd$+$d^a$gd$+Lkd$$If0p#/ | 4 aS$d$Ifa$gdqW7Vd$IfVD^Vgd$+Գ+,PQRShijwx$d$$&dIfPa$gdqW7&d$$If^`&gdqW7$\d$VDQ^\`a$gd$+$\#d$VDQ^\`#a$gd$+QR´ $%,-45<=>ͻ͏uufT#hgh$+CJPJaJnHo(tHhgh$+hewCJaJo(hgh$+hewCJaJhgh$+CJaJo(#hghbfCJPJ]aJnHtHhgh$+h CJaJhgh$+CJ]aJ#hgh$+CJPJ]aJnHtHhgh$+CJaJhgh$+>*CJaJ hgh$+CJPJaJnHtHhgh$+CJaJ´ô,&d$$If^`&gdqW7kd,$$If֞  yU"5&Nnnnn0p#4 aSô˴Ӵ۴$d$$Ifa$gdqW7oԦ$d$$Ifa$gdqW7,&d$$If^`&gdqW7kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdqW7oԦ$d$$Ifa$gdqW7,&d$$If^`&gdqW7kd$$If֞  yU"5&Nnnnn0p#4 aS $d$$Ifa$gdqW7oԦ$d$$Ifa$gdqW7 ,&d$$If^`&gdqW7oԦkd$$If֞  yU"5&Nnnnn0p#4 aS%-5=?I$d$$Ifa$gdqW7>?HIJK^õĵ͵εϵеֵ׵ߵƴwƨlƨwwwwwƨlƨlllhgh$+CJaJ hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tHhgh$+hewCJaJhgh$+CJ]aJ#hgh$+CJPJ]aJnHtHhgh$+CJaJhgh$+hewCJaJo(hgh$+CJaJo(&hgh$+hewCJPJaJnHtH*IJ^,hd$$IfVDWD^`hgd$+kdޗ$$If֞  yU"5&Nnnnn0p#4 aS^emt|$d$$&dIfPa$gdqW7,&d$$If^`&gdqW7kdҘ$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdqW7,hd$$IfVDWD^`hgd$+kdƙ$$If֞  yU"5&Nnnnn0p#4 aSĵε$d$$&dIfPa$gdqW7εϵе,&d$$If^`&gdqW7kd$$If֞  yU"5&Nnnnn0p#4 aSеѵҵӵԵյֵ$d$$Ifa$gdqW7ֵ׵,hd$$IfVDWD^`hgd$+kd$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdqW7$d$$&dIfPa$gdqW7,&d$$If^`&gdqW7kd$$If֞  yU"5&Nnnnn0p#4 aS+/0678KLMQRSY[\jnoxyĶŶ̶ͶζпБппББ޿k&hgh$+hewCJPJaJnHtH#hgh$+CJPJaJnHo(tH&hgh$+CJPJ]aJnHo(tHhgh$+CJaJo(hgh$+hewCJaJ hgh$+CJPJaJnHtHhgh$+CJ]aJo(hgh$+CJaJhgh$+CJ]aJhgh$+CJaJ*$d$$Ifa$gdqW7+,ad$$If^`agdqW7kd$$If֞  yU"5&Nnnnn0p#4 aS+,-./07$d$$Ifa$gdqW778M,ad$$If^`agdqW7kd$$If֞  yU"5&Nnnnn0p#4 aSMNOPQR[$d$$Ifa$gdqW7[\j,ad$$If^`agdqW7kd~$$If֞  yU"5&Nnnnn0p#4 aSjklmnox$d$$Ifa$gdqW7xy,ad$$If^`agdqW7kdr$$If֞  yU"5&Nnnnn0p#4 aS$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7,&d$$If^`&gdqW7kdf$$If֞  yU"5&Nnnnn0p#4 aS$d$$Ifa$gdqW7,ad$$If^`agdqW7kdZ$$If֞  yU"5&Nnnnn0p#4 aS¶öĶŶ̶$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7̶Ͷζ,&d$$If^`&gdqW7kdN$$If֞  yU"5&Nnnnn0p#4 aSζ϶жѶҶӶԶ$d$$Ifa$gdqW7oԦ$d$$Ifa$gdqW7ζԶնֶ׶cklŷǻxfZL:f#hghAsCJPJ]aJnHtHhgh$+h CJaJhgh$+CJ]aJ#hgh$+CJPJ]aJnHtHhgh$+>*CJaJ hgh$+CJPJaJnHtH&hgh$+>*CJPJaJnH o(tH "hgh$+>*CJaJnH o(tH hgh$+>*CJaJ#hgh$+>*CJPJaJnHtH hgh$+CJPJaJnHtHhgh$+CJaJhgh$+CJaJԶնֶ,'gd$+kdP$$If֞  yU"5&Nnnnn0p#4 aSֶ!"8TUVcdek$d$$&dIfPa$gdqW7&d$$If^`&gdqW7$\d$VDQ^\`a$gd$+$\.d$VDQ^\`.a$gd$+klm,&d$$If^`&gdqW7kdL$$If֞ 9!%3nnn0"4 aSmu}$d$$Ifa$gdqW7oԦ$d$$Ifa$gdqW7,&d$$If^`&gdqW7kdV$$If֞ 9!%3nnn0"4 aS$d$$Ifa$gdqW7oԦ$d$$Ifa$gdqW7,&d$$If^`&gdqW7kdZ$$If֞ 9!%3nnn0"4 aS$d$$Ifa$gdqW7oԦ$d$$Ifa$gdqW7ŷ,&d$$If^`&gdqW7kdd$$If֞ 9!%3nnn0"4 aSŷηϷַ׷޷  $%(),-./0129;@AIKQRY]^`abcfgjklmnqٽȽhgh$+CJ]aJ#hgh$+CJPJ]aJnHtHhgh$+CJaJ hgh$+CJPJaJnHtH&hgh$+hewCJPJaJnHtH#hgh$+CJPJaJnHo(tH>ŷϷ׷߷$d$$Ifa$gdqW7,hd$$IfVD&WD^`hgd$+kdn$$If֞ 9!%3nnn0"4 aS$.0$d$$&dIfPa$gdqW7012,&d$$If^`&gdqW7kd~$$If֞ 9!%3nnn0"4 aS2345678$d$$Ifa$gdqW789@,hd$$IfVDWD^`hgd$+kd$$If֞ 9!%3nnn0"4 aS@JRZblv$d$$&dIfPa$gdqW7qrvwxȸϸиԸո׸ظ۸ݸų܋ܙѥw܋ѥw܋&hgh$+CJPJ]aJnHo(tHhgh$+hewCJaJhgh$+CJaJo(hgh$+CJ]aJo(#hgh$+CJPJ]aJnHtHhgh$+CJ]aJhgh$+CJaJ hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tH.vwx,&d$$If^`&gdqW7kd$$If֞ 9!%3nnn0"4 aSxyz{|}~$d$$Ifa$gdqW7~,hd$$IfVDWD^`hgd$+kd$$If֞ 9!%3nnn0"4 aS$d$$Ifa$gdqW7$d$$&dIfPa$gdqW7,&d$$If^`&gdqW7kd$$If֞ 9!%3nnn0"4 aS$d$$Ifa$gdqW7и,hd$$IfVDWD^`hgd$+kdί$$If֞ 9!%3nnn0"4 aSиѸҸӸԸոܸ$d$$Ifa$gdqW7ܸݸ,hd$$IfVDWD^`hgd$+kdް$$If֞ 9!%3nnn0"4 aS$d$$Ifa$gdqW7>BCIJKOQReijmnoqrst*8G^_moõõÉxmxmx[xm#hgh$+CJPJaJnHo(tHhgh$+CJaJ hgh$+CJPJaJnHtH&hgh$+hewCJPJaJnHtHhgh$+CJ]aJhgh$+CJaJo(hgh$+hewCJaJ hgh$+CJPJaJnHtHhgh$+CJ]aJo(hgh$+CJaJ#hgh$+CJPJaJnHo(tH!,hd$$IfVDWD^`hgd$+kd$$If֞ 9!%3nnn0"4 aS$d$$Ifa$gdqW7>,hd$$IfVDWD^`hgd$+kd$$If֞ 9!%3nnn0"4 aS>?@ABCI$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7IJK,hd$$IfVDWD^`hgd$+kd$$If֞ 9!%3nnn0"4 aSKLMNOPQ$d$$Ifa$gdqW7QRe,hd$$IfVDWD^`hgd$+kd$$If֞ 9!%3nnn0"4 aSefghijr$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7rst,'gd$+kd.$$If֞ 9!%3nnn0"4 aSo  !"#78EFwױmaPEPEPEhgh$+CJaJ hgh$+CJPJaJnHtHhgh$+CJ]aJ&hgh$+>*CJPJaJnH o(tH "hgh$+>*CJaJnH o(tH hgh$+>*CJaJ#hgh$+>*CJPJaJnHtH&hgh% A>*CJPJaJnHo(tH#hgh$+5CJPJaJnHtH hgh$+CJPJaJnHtHhgh$+CJaJhgh$+CJaJo(tRS !"#&d$$If^`&gdqW7gd$+$\d$VDQ^\`a$gd$+$\#d$VDQ^\`#a$gd$+ WDh`gd$+$dWDh^`a$gd$+$d^a$gd$+#89F\xy$d$$&dIfPa$gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kdL$$Ifֈ sok $ Hnt0"4 aSɼʼѼҼټڼ *26@ABH\cdjkxyʸ֧֧hgh$+h CJ]aJ)hgh$+h^TCJPJ]aJnHtH hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tHhgh$+CJaJo(#hgh$+CJPJ]aJnHtHhgh$+CJaJhgh$+CJ]aJ/0kdF$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdqW7$d$$Ifa$gdqW7&d$$If^`&gdqW7?+&d$$If^`&gdqW7kd:$$Ifֈ sok $ Hnt0"4 aSʼҼڼ$d$$Ifa$gdqW7$d$$4$Ifa$gdqW7 ?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd.$$Ifֈ sok $ Hnt0"4 aS $d$$&dIfPa$gdqW7$d$$Ifa$gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd($$Ifֈ sok $ Hnt0"4 aS0kd"$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdqW723456@$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7&d$$If^`&gdqW7@ABC?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd$$Ifֈ sok $ Hnt0"4 aSCDEFGH0kd$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdqW7H\dkry$d$$Ifa$gdqW7&d$$If^`&gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd$$Ifֈ sok $ Hnt0"4 aS$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd $$Ifֈ sok $ Hnt0"4 aSƽҽս߽TU~ͻuiWK9#hgh$+CJPJaJnHo(tHhgh$+CJaJo("hgh$+>*CJaJnH o(tH hgh$+>*CJaJ#hgh$+>*CJPJaJnHtH hgh$+CJPJaJnHtHhgh$+CJaJo(hgh$+CJaJhgh$+CJ]aJ#hgh$+CJPJ]aJnHtHhgh$+CJaJ&hgh$+h5CJPJaJnHtH&hgh$+h CJPJaJnHtH0kd$$Ifֈ sok $ Hnt0"4 aS$d$$Ifa$gdqW7ҽӽԽսֽ$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7&d$$If^`&gdqW7?:%$\#d$VDQ^\`#a$gd$+gd$+kd $$Ifֈ sok $ Hnt0"4 aS 0LMS$d$$&dIfPa$gdqW7&d$$If^`&gdqW7STU?+&d$$If^`&gdqW7kd$$Ifֈ/ wQ$j Hnt0!4 aSU]emu}$&d$$If^`&a$gdqW7}~?+++&d$$If^`&gdqW7kd$$Ifֈ/ wQ$j Hnt0!4 aS+kd$$Ifֈ/ wQ$j Hnt0!4 aS&d$$If^`&gdqW7$d$$Ifa$gdqW7&d$$If^`&gdqW7;޾ 0789;<?@ABCGLMNUWcxֳֳ֡֡֡֡#hgh$+CJPJ]aJnHtH#hghAqCJPJ]aJnHtH hgh$+CJPJaJnHtHhgh$+CJaJ#hgh$+CJPJaJnHo(tHhgh$+CJaJo(;޾߾?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd $$Ifֈ/ wQ$j Hnt0!4 aS߾$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd($$Ifֈ/ wQ$j Hnt0!4 aS0kd0$$Ifֈ/ wQ$j Hnt0!4 aS$d$$Ifa$gdqW7 $d$$&dIfPa$gdqW7$d$$Ifa$gdqW7&d$$If^`&gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd8$$Ifֈ/ wQ$j Hnt0!4 aS0kd@$$Ifֈ/ wQ$j Hnt0!4 aS$d$$Ifa$gdqW708@GNV$d$$Ifa$gdqW7&d$$If^`&gdqW7VWz{?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kdH$$Ifֈ/ wQ$j Hnt0!4 aSxyz~qǻuauV؞ǩǩE hgh$+CJPJaJnHtHhgh$+CJaJ&hgh$+h5CJPJaJnHtH&hgh$+h CJPJaJnHtH)hgh$+h CJPJ]aJnHtHhgh$+CJaJ#hgh$+CJPJaJnHo(tHhgh$+CJaJo( hgh$+CJPJaJnHtH#hgh$+CJPJ]aJnHtH)hgh$+h^TCJPJ]aJnHtH{|}~$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kdP$$Ifֈ/ wQ$j Hnt0!4 aS0kdX$$Ifֈ/ wQ$j Hnt0!4 aS$d$$Ifa$gdqW7$d$$&dIfPa$gdqW7$d$$Ifa$gdqW7&d$$If^`&gdqW7?:,$`VDh^`a$gd$+gd$+kd`$$Ifֈ/ wQ$j Hnt0!4 aS56{|j$d$$&dIfPa$gdqW7&d$$If^`&gdqW7$`VDh^`a$gd$+$\d$VDQ^\`a$gd$+$\#d$VDQ^\`#a$gd$+|`gd$+$d^a$gd$+$ & F da$gd$+ VD^gd$+ qt~BST34Ű|p^"hgh$+>*CJaJnH o(tH hgh$+>*CJaJ#hgh$+>*CJPJaJnHtHhgh$+CJaJnH o(tH #hgh$+5CJPJaJnHtH(hgh$+CJOJPJQJaJnHtHhgh$+CJaJhgh$+CJaJo( hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tH456z{| 189?@Unot01YZl~˿|||n||hghomCJ]aJo(hgh$+CJ]aJo(hgh$+CJaJo(#hgh$+CJPJ]aJnHtHhgh$+CJaJhgh$+CJ]aJhgh$+CJaJo( hgh$+CJPJaJnHtHhgh$+CJaJnH o(tH &hgh$+>*CJPJaJnH o(tH +$d$$&dIfPa$gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kdh$$IfֈB>:!% Hnt0"4 aS0kdb$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7 $d$$Ifa$gdqW7&d$$If^`&gdqW7 19@?3$$$d$$Ifa$gdqW7 d$$IfgdqW7kdV$$IfֈB>:!% Hnt0"4 aS@FNVW0kdJ$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7W$d$$Ifa$gdqW7&d$$If^`&gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kdD$$IfֈB>:!% Hnt0"4 aS&)010kd>$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW71lnpvx~$d$$Ifa$gdqW7&d$$If^`&gdqW7~?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd8$$IfֈB>:!% Hnt0"4 aS~ ?Vz}o]Qhgh$+>*CJaJ#hgh$+>*CJPJaJnHtH&hghx :>*CJPJaJnHo(tHhgh$+CJaJhgh$+CJaJo( hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tHhgh$+CJ]aJhgh$+CJaJo(#hgh$+CJPJ]aJnHtHhgh$+CJ]aJo(hgh$+CJaJ0kd2$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7$d$$&dIfPa$gdqW7&d$$If^`&gdqW7?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd,$$IfֈB>:!% Hnt0"4 aS0kd4$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7$d$&dIfPa$gdqW7d$If^`gdqW7$HdVD^^Ha$gd$+HdVD^^Hgd$+$\#dVDQ^\`#a$gd$+$>dVDaWD^`>a$gd$+",-.4589?@AQhiźwk\k\k\k\kPkkhgh$+CJ]aJhgh$+hewCJaJo(hgh$+CJaJo(&hgh$+CJPJ]aJnHo(tH#hgh$+CJPJ]aJnHtHhgh$+>*CJaJ hgh$+CJPJaJnHtHhgh$+CJaJhgh$+CJaJo( hgh$+CJPJaJnHtHhgh$+>*CJPJaJo(hgh$+>*CJaJo(?+$d$Ifa$gdqW7d$If^`gdqW7kd6$$Ifֈ F % no0V"4 aS 0kd*$$Ifֈ F % no0V"4 aS$d$Ifa$gdqW7 $d$Ifa$gdqW7d$If^`gdqW7,.?+$d$Ifa$gdqW7d$If^`gdqW7kd$$Ifֈ F % no0V"4 aS.579@A0kd $$Ifֈ F % no0V"4 aS$d$Ifa$gdqW7AQW[^bh$d$Ifa$gdqW7d$If^`gdqW7hi?'sd$IfVDWD^`sgd$+kd$$Ifֈ F % no0V"4 aS$d$$Ifa$gdqW7?+$d$Ifa$gdqW7d$If^`gdqW7kd$$Ifֈ F % no0V"4 aS0kd $$Ifֈ F % no0V"4 aS$d$Ifa$gdqW74567YZ[)*0WXYZ]^_`adehoqrstɶ{{{iiiiXiXii hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tHhgh$+CJ]aJ hgh$+CJPJaJnHtHhgh$+>*CJaJ#hgh$+>*CJPJaJnHtH%hgh$+5CJ\aJnH o(tH hgh$+CJaJhgh$+CJaJo(#hgh$+CJPJ]aJnHtHhgh$+CJ]aJo("#+4$d$&dIfPa$gdqW7d$If^`gdqW7456?0;WD^`;gd$+kd $$Ifֈ F % no0V"4 aS6Z[$d$$&dIfPa$gdqW7&d$$If^`&gdqW7gd$+$`VDh^`a$gd$+;WD^`;gd$+$\#d$VDQ^\`#a$gd$+ ?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd$$IfֈB>:!% Hnt0"4 aS ()0kd$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7)*+,-./$d$$Ifa$gdqW7&d$$If^`&gdqW7/0W^e?3$$$d$$Ifa$gdqW7 d$$IfgdqW7kd$$IfֈB>:!% Hnt0"4 aSeipxy0kd$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7tw()*-./02345678=?Zef|}~ܼܪ󪙪腼sghghomCJ]aJ#hghomCJPJ]aJnHtH&hgh$+CJPJ]aJnHo(tH hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tH#hgh$+CJPJ]aJnHtHhgh$+CJ]aJo(hgh$+CJ]aJhgh$+CJaJhgh$+CJaJo(#y$d$$Ifa$gdqW7&d$$If^`&gdqW7)/?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd$$IfֈB>:!% Hnt0"4 aS/468>?0kd$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7?fjotv|$d$$Ifa$gdqW7&d$$If^`&gdqW7|}?+$d$$Ifa$gdEP&d$$If^`&gdqW7kd$$IfֈB>:!% Hnt0"4 aS7=>?@JKLfklqruv{|}~ȷȷȚȚԆԥԥ&hghomCJPJ]aJnHo(tHhghomCJaJ#hghomCJPJaJnHo(tH hghomCJPJaJnHtHhghomCJaJo(#hghomCJPJ]aJnHtHhghomCJ]aJhghomCJ]aJo(-$d$$Ifa$gdEP7>?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd$$IfֈB>:!% Hnt0"4 aS>@BDKL0kd$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7Lflrtv|$d$$&dIfPa$gdqW7&d$$If^`&gdqW7|}~?+$d$$Ifa$gdqW7&d$$If^`&gdqW7kd$$IfֈB>:!% Hnt0"4 aS0kd$$IfֈB>:!% Hnt0"4 aS$d$$Ifa$gdqW7WX|}(>Z[a$d$&dIfPa$gdqW7d$If^`gdqW7HdVD^^Hgd$+$HdVD^^Ha$gd$+$>dVDaWD^`>a$gd$+ %/;VWXY{}abܵvj_NBhgh$+>*CJaJ hgh$+CJPJaJnHtHhgh$+CJaJhgh$+CJaJo( hgh$+CJPJaJnHtHhghomCJaJnH o(tH hghom>*CJaJ#hghom>*CJPJaJnHtHhgh$+CJaJnH o(tH hgh$+CJaJhgh$+CJaJo( hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tHabck?+$d$Ifa$gdqW7d$If^`gdqW7kd$$Ifֈ F % no0V"4 aSks{0kd$$Ifֈ F % no0V"4 aS$d$Ifa$gdqW7$d$Ifa$gdqW7d$If^`gdqW7?+$d$Ifa$gdqW7d$If^`gdqW7kd$$Ifֈ F % no0V"4 aSb!"#$&'()*+,㽩㘽znnnhgh$+CJaJo(hgh$+CJ]aJ#hgh;CJPJaJnHo(tH hgh$+CJPJaJnHtH&hgh$+hewCJPJaJnHtH#hgh$+CJPJaJnHo(tH&hgh$+CJPJ]aJnHo(tH#hgh$+CJPJ]aJnHtHhgh$+CJaJ+0kd$$Ifֈ F % no0V"4 aS$d$Ifa$gdqW7$d$Ifa$gd;$d$Ifa$gdqW7d$If^`gdqW7!?'sd$IfVDWD^`sgd$+kd$$Ifֈ F % no0V"4 aS!)159B$d$$Ifa$gdqW7,/236789:<=@BCQRSXYZ[`abcehijklmnorstuƴƴƢ hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tH#hgh$+CJPJ]aJnHtHhgh$+CJaJ#hgh$+CJPJaJnHo(tHhgh$+CJaJo( hgh$+CJPJaJnHtH9BCQZ?+$d$Ifa$gdqW7d$If^`gdqW7kd$$Ifֈ F % no0V"4 aSZbgktu0kd$$Ifֈ F % no0V"4 aS$d$Ifa$gdqW7u$d$&dIfPa$gdqW7d$If^`gdqW7?..6VDWD^`6gd$+kd$$Ifֈ F % no0V"4 aS)*+LMNSXeMkd$$If40#& 9!4 aSf4%$!d$Ifa$gdqW7$d$IfWD^`$gdqW76VDWD^`6gd$+$HdVD^^Ha$gd\T &*+KLNQSXs}ܿu_SܿSܿSܿSܿShgh$+CJaJo(*hgh$+>*CJOJQJaJnHo(tH*hgh$+>*CJOJQJaJnH o(tH hgh$+>*CJOJQJaJhgh$+CJOJQJaJ(hgh$+CJOJPJQJaJnHtHhgh$+CJaJ#hgh\TCJPJaJnHo(tH hgh$+CJPJaJnHtH#hgh$+CJPJaJnHo(tH XYZbj||$d$Ifa$gdqW7$d$IfWD^`$gdqW7]kdW$$IfFu#&9!    4 aSjklmn$d$Ifa$gdqW7 d$IfgdqW7]kd$$IfFu#&9!    4 aSnos}$d$Ifa$gdqW7 d$IfgdqW7]kdc$$IfFu#&9!    4 aS$d$Ifa$gdqW7 d$IfgdqW7]kd$$IfFu#&9!    4 aS$d$Ifa$gdqW7 d$IfgdqW7]kdo$$IfFu#&9!    4 aS}}$d$&dIfPa$gdqW7 d$IfgdqW7]kd$$IfFu#&9!    4 aS$d$Ifa$gdqW7 d$IfgdqW7]kd$$IfFu#&9!    4 aS}}$d$&dIfPa$gdqW7 d$IfgdqW7]kd $$IfFu#&9!    4 aS__#9TPL HD@<+{^$d^a$gd$+$d^a$gd$+]kd$$IfFu#&9!    4 aS L7Bî|h]Mhghx :>*CJOJQJaJhghx :CJaJ&hghx :5CJPJ\aJnHtHhgh[5CJ\aJ)hgh[5CJPJ\aJnHo(tHhgh[5CJ\aJo((hghomB*CJOJQJaJo(ph(hghO%?B*CJOJQJaJo(phhgh$+CJaJo( hgh$+CJPJaJnHtHhgh$+CJaJaRR$d$Ifa$gdqW7]kd$$IflF$&!    4 la1%$!d$Ifa$gdqW7Hd$If^H`gdqW7dgdx :d^`gd[  7DEF|ɸɕɕɕɕɃɕɕɃwwwwwhhgh[5CJ\aJo(hghx :CJaJo(#hghx :CJPJaJnHo(tH hghx :CJPJaJnHtH#hghx :>*CJOJPJQJaJ hghx :CJOJPJQJaJhghx :CJaJ*hghx :>*CJOJQJaJnHo(tH*hghx :>*CJOJQJaJnH o(tH (xx'$ d$Ifa$gdqW7Hd$If^H`gdqW7]kd$$IflF$&!    4 la1 xx'$ d$Ifa$gdqW7Hd$If^H`gdqW7]kd$$IflF$&!    4 la1 7>E{{$d$Ifa$gdqW7d$IfWDd`gdqW7bkd$$IflF$&!    4 la1gN &EF|pp$d$&dIfPa$gdqW7 & F=d$1$If^=`gdx :]kd$$IflF$&!    4 la1$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1}}$d$&dIfPa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1}}$d$&dIfPa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1 yeQQ%$!d$Ifa$gdqW7Hd$If^H`gdqW70d^`0gdxd^`gd[dgdx :]kd$$IflF$&!    4 la1 "EFMNOPTZ[afg²‹yymymy\ymy\mymy\my\ hghxCJPJaJnHtHhghxCJaJo(#hghxCJPJaJnHo(tH hghxCJOJPJQJaJ*hghx>*CJOJQJaJnH o(tH hghx>*CJOJQJaJhghxCJaJhgh[5CJ\aJhgh[5CJ\aJo()hgh[5CJPJ\aJnHo(tH$ ~~$d$Ifa$gdqW7Hd$If^H`gdqW7]kd$$IflF$&!    4 la1 !"xx'$ d$Ifa$gdqW7Hd$If^H`gdqW7]kd$$IflF$&!    4 la1"#=>?$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1?@MT[$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1[\}}$d$&dIfPa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1}}$d$&dIfPa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1~~#$d$Ifa$gdqW7Hd$If^H`gdqW7]kd$$IflF$&!    4 la1pp$d$&dIfPa$gdqW7%!Hd$If^H`gdqW7]kd$$IflF$&!    4 la1\em{}JTVnZ^ȷڷڷڷڷwf hghznCJPJaJnHtHhghznhF JCJaJhghznCJaJo(hghznCJaJ4hgh[B*CJOJPJQJaJnHo(phtH hghxCJPJaJnHtH#hghxCJPJaJnHo(tHhghxCJaJo(hghxCJOJQJaJhghxCJaJ'~novR#9TPL HD@<+{^$dVD,^a$gdzn$d^a$gdx $da$gdx]kd$$IflF$&!    4 la1 "paa$d$Ifa$gdqW7]kd$$IflF$&!    4 la1%$!d$Ifa$gdqW7 d$IfgdqW7$`dVDh^`a$gdzn  $&8:@HIUYtwxy|~ŭ٢tbRtbtbbthghznCJaJnH o(tH #hghznCJPJaJnHo(tHhghznCJaJo( hghznCJPJaJnHtH hghznCJOJPJQJaJhghznCJaJ.hghzn>*CJOJPJQJaJnHo(tH'hghznCJOJQJaJnH o(tH *hghzn>*CJOJQJaJnH o(tH hghzn>*CJOJQJaJ "#$%&'$ d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1&':AI{{$d$&dIfPa$gdqW7 d$IfgdqW7_kd|$$IfltF$&!    4 la1IJKLM#$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1MN#$d$Ifa$gdqW7 d$IfgdqW7]kdz$$IflF$&!    4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1>?BCDIJ|})*-12Kamnpqz{|&hghznhi4CJPJaJnHtH)hghznhi4CJPJaJnHo(tHhghznCJaJ hghznCJPJaJnHtHhghznCJaJo(#hghznCJPJaJnHo(tH< #$d$Ifa$gdqW7 d$IfgdqW7]kdz$$IflF$&!    4 la1>DJ#$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1JK|#$d$Ifa$gdqW7 d$IfgdqW7]kdz$$IflF$&!    4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflF$&!    4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kdz $$IflF$&!    4 la1-02#$d$Ifa$gdqW7 d$IfgdqW7]kd $$IflF$&!    4 la123qu{#$d$Ifa$gdqW7 d$IfgdqW7]kdz $$IflF$&!    4 la1{|#$d$Ifa$gdqW7 d$IfgdqW7]kd $$IflF$&!    4 la1}}#$d$&dIfPa$gdqW7 d$IfgdqW7]kdz $$IflF$&!    4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd $$IflF$&!    4 la1h|ҽұᎇreP;)hgh% A5CJPJ\aJnHo(tH)hghzn5CJPJ\aJnHo(tHhghznh<^5\hghznPJnHtHhghzno( hghzn hghznCJPJaJnHtH#hghznCJPJaJnHo(tHhghznCJaJo((hghznCJOJPJQJaJnHtHhghznCJOJQJaJhghznCJaJ&hghznhCJPJaJnHtHxx$d$&dIfPa$gdqW7%!d$IfgdqW7]kdz $$IflF$&!    4 la1qaad^`gdN$RdVDb^Ra$gdY$dVDbWD^`a$gdzndgdzn]kd $$IflF$&!    4 la1578;=?BKLe67DE[Ͳmm\\J\J\JJJ\J#hgh CJPJaJnHo(tH hgh CJPJaJnHtH*hgh >*CJOJQJaJnH o(tH hgh >*CJOJQJaJ&hgh 5CJPJ\aJnHtHhgh CJaJ4hghpMSB*CJOJPJQJaJnHo(phtHhghN5CJ\aJ)hghN5CJPJ\aJnHo(tHhghN5CJ\aJo(678=BC?]kdz$$IflF$&!    4 la1%$!d$Ifa$gdqW7d$IfWD^`gdqW7dgd  d`gd #9TPL HD@<+{^CDLTUVWX|mm#$d$Ifa$gdqW7]kd$$IflF$&!    4 la1$d$Ifa$gdqW7d$IfWD^`gdqW7XYzz#$d$Ifa$gdqW7sd$IfVDWD^`sgd ]kdt$$IflF$&!    4 la1zz#$d$Ifa$gdqW7sd$IfVDWD^`sgd ]kd$$IflF$&!    4 la1zz#$d$Ifa$gdqW7sd$IfVDWD^`sgd ]kdn$$IflF$&!    4 la1]_cqq#$d$&dIfPa$gdqW7sd$IfVDWD^`sgd ]kd$$IflF$&!    4 la1[\_ch :ABDEHIZabdr789@Bghgh CJaJhgh CJaJo(#hgh CJPJaJnHo(tH hgh CJPJaJnHtHMcdefgzz#$d$Ifa$gdqW7sd$IfVDWD^`sgd ]kdn$$IflF$&!    4 la1ghqq#$d$&dIfPa$gdqW7sd$IfVDWD^`sgd ]kd$$IflF$&!    4 la1zz#$d$Ifa$gdqW7sd$IfVDWD^`sgd ]kdn$$IflF$&!    4 la1zz#$d$Ifa$gdqW7sd$IfVDWD^`sgd ]kd$$IflF$&!    4 la1 zz#$d$Ifa$gdqW7sd$IfVDWD^`sgd ]kdn$$IflF$&!    4 la1 :>Bqq#$d$&dIfPa$gdqW7sd$IfVDWD^`sgd ]kd$$IflF$&!    4 la1BCDEFGrr#$d$$Ifa$gdqW7sd$$IfVDWD^`sgd d$gd ]kdn$$IflF$&!    4 la1GHuu#$d$$Ifa$gdqW7sd$$IfVDWD^`sgd bkd$$IflF$&!    4 la1g&#$d$$Ifa$gdqW7 & Fd$$1$Ifgd ]kdx$$IflF$&!    4 la1xx#$d$$&dIfPa$gdqW7 & Fd$$1$Ifgd ]kd$$IflF$&!    4 la1#$d$$Ifa$gdqW7d$$If^gdqW7]kdl$$IflF$&!    4 la1}}#$d$$&dIfPa$gdqW7 d$$IfgdqW7]kd$$IflF$&!    4 la1#$d$$Ifa$gdqW7 d$$IfgdqW7]kd`$$IflF$&!    4 la19;A#$d$$Ifa$gdqW7 d$$IfgdqW7]kd$$IflF$&!    4 la1ABzzzz#$d$$Ifa$gdqW7sd$$IfVDWD^`sgd ]kdT$$IflF$&!    4 la1nn$sd$$IfVDWD^`sa$gd sd$$IfVDWD^`sgd ]kd$$IflF$&!    4 la1&zzzz#$d$$Ifa$gdqW7sd$$IfVDWD^`sgd ]kdH$$IflF$&!    4 la1%'Tghijlorz{|}~ϾϾqccUJ:hghr>*CJOJQJaJhghrCJaJhghr5CJ\aJhgh 5CJ\aJ)hgh 5CJPJ\aJnHo(tHhgh 5CJ\aJo(hghom5CJ\aJo(hgh 5CJ\aJo(hgh CJaJ hgh CJPJaJnHtH#hgh CJPJaJnHo(tHhgh CJaJo(#hgh% ACJPJaJnHo(tH&'T^hqq#$d$$&dIfPa$gdqW7sd$$IfVDWD^`sgd ]kd$$IflF$&!    4 la1hijkl|}~kWW%$!d$$Ifa$gdqW7{d$$IfWD^{`gdqW7d$gdrd^`gd d$gd ]kdB$$IflF$&!    4 la1 ')/289;`xy}ϾϾϭϭϝϭϋϭm#hghZCJPJaJnHo(tHhghrCJaJo(#hghrCJPJaJnHo(tHhghrCJaJnH o(tH hghrCJPJaJnHtH hghrCJOJPJQJaJhghrCJaJhghr>*CJOJQJaJ*hghr>*CJOJQJaJnH o(tH '||$d$$Ifa$gdqW7{d$$IfWD^{`gdqW7]kd$$IflF$&!    4 la1vv'$ d$$Ifa$gdqW7{d$$IfWD^{`gdqW7]kd6$$IflF$&!    4 la1vv'$ d$$Ifa$gdqW7{d$$IfWD^{`gdqW7]kd$$IflF$&!    4 la1'()0129ssssss$d$$&dIfPa$gdqW7Pd$$IfWD^`PgdqW7]kd0$$IflF$&!    4 la1 9:; 23~nn___$d$^a$gd"sd^`gd d$gd]$d$^a$gdr d$^gdr]kd$$IflF$&!    4 la1   XeuųvjvjvYvjvj hgh"sCJPJaJnHtHhgh"sCJaJo(hgh"sCJaJhgh 5CJ\aJ)hgh 5CJPJ\aJnHo(tHhgh 5CJ\aJo(#hgh]CJPJaJnHo(tH hghrCJPJaJnHtHhghrCJaJo(hghrCJaJ#hgh9LCJPJaJnHo(tH3ŵŵŵqbWhghvNCJaJhghvN5CJ\aJo(hgh 5CJ\aJ)hgh 5CJPJ\aJnHo(tHhgh 5CJ\aJo(#hgh]CJPJaJnHo(tHhgh"sCJaJnH o(tH hgh"sCJaJ hgh"sCJPJaJnHtHhgh"sCJaJo(#hgh"sCJPJaJnHo(tH"$g]kd$$$IflFB"}     4 la1$d$Ifa$gdqW7 d$IfgdqW7dgdvNdgd $d$^a$gd]  )MTUy󰤒rr_$hghvNCJOJQJaJnHtHhghvNCJOJQJaJ hghvNCJPJaJnHtH#hghvNCJPJaJnHo(tHhghvNCJaJo(hghvNCJaJ#hghvN>*CJPJaJnHtH&hghvN>*CJPJaJnH o(tH "hghvN>*CJaJnH o(tH hghvN>*CJaJ%$%&'(#$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflFB"}     4 la1()EMU#$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflFB"}     4 la1UVuu#$d$&dIfPa$gdqW7d$If^`gdqW7]kdh$$IflFB"}     4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd$$IflFB"}     4 la1xx$d$&dIfPa$gdqW7%!d$IfgdqW7]kdL$$IflFB"}     4 la1 $$Ifa$gdqW7%!$IfgdqW7]kd$$IflFB"}     4 la1}} $$Ifa$gdqW7%!$IfWD^`gdqW7]kd0$$IflFB"}     4 la1/35>?@ADEGHKRSTUXz}~9QTV[nqtv*loҒhghvNCJaJnH o(tH (hghvNCJOJPJQJaJnHtHhghvNCJOJQJaJhghvNCJaJo(#hghvNCJPJaJnHo(tHhghvNCJaJ hghvNCJPJaJnHtH9/7?uu#$d$&dIfPa$gdqW7d$If^`gdqW7]kd$$IflFB"}     4 la1?@ABC $$Ifa$gdqW7%!$IfgdqW7]kd $$IflFB"}     4 la1CDELS~~$$&dIfPa$gdqW7%!$IfgdqW7]kd $$IflFB"}     4 la1STUVW $$Ifa$gdqW7%!$IfgdqW7]kd $$IflFB"}     4 la1WXz~~$$&dIfPa$gdqW7%!$IfgdqW7]kdj!$$IflFB"}     4 la1pYY$ d7$8$H$^` a$gdvN$ldWD^`la$gdvN$ 7$8$H$^` a$gdvNdgdvN]kd!$$IflFB"}     4 la1%^ht+1678fglop$hghvNCJOJQJaJnHtH&hghvN>*CJPJaJnH o(tH "hghvN>*CJaJnH o(tH hghvN>*CJaJ#hghvNCJPJaJnHo(tHhghvNCJaJo( hghvNCJPJaJnHtHhghvNCJaJ,]kdN"$$IflFB"}     4 la1$d$Ifa$gdqW7 d$IfgdqW7#$d$Ifa$gdqW7 d$IfgdqW7]kd"$$IflFB"}     4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd&#$$IflFB"}     4 la1+17zz#$d$Ifa$gdqW7%!$IfWD^`gdqW7]kd#$$IflFB"}     4 la178flpzz#$d$Ifa$gdqW7%!$IfWD^`gdqW7]kd$$$IflFB"}     4 la1pq}}#$d$&dIfPa$gdqW7 d$IfgdqW7]kdv$$$IflFB"}     4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd$$$IflFB"}     4 la1xx$d$&dIfPa$gdqW7%!d$IfgdqW7]kdZ%$$IflFB"}     4 la1#'(.3473;<GfhjlstuvL·߷߷ӷӷ߷·ӷӷӷӷӷӷߧӷӷ&hghvN>*CJPJaJnHo(tHhghvN>*CJaJhghvNCJaJnH o(tH hghvNCJaJ hghvNCJPJaJnHtHhghvNCJaJo(#hghvNCJPJaJnHo(tHhghvNCJOJQJaJ0KLk_ d$IfgdqW7$d7$8$H$^`a$gdvNd^`gdvN$d^a$gdvN]kd%$$IflFB"}     4 la1 367:;RSTVW\bhino%gjmnoqst÷ÁÁ÷ÁåÔ$hghvNCJOJQJaJnHtH hghvNCJPJaJnHtH#hghvNCJPJaJnHo(tHhghvNCJaJo(hghvNCJaJhghvN>*CJaJ&hghvN>*CJPJaJnH o(tH "hghvN>*CJaJnH o(tH 2 d$IfgdqW7]kd>&$$IflFB"}     4 la1$d$Ifa$gdqW7#$d$Ifa$gdqW7 d$IfgdqW7]kd&$$IflFB"}     4 la1u#$d$Ifa$gdqW7#$d$4$Ifa$gdqW7 d$IfgdqW7]kd'$$IflFB"}     4 la1zz#$d$Ifa$gdqW7%!$IfWD^`gdqW7]kd'$$IflFB"}     4 la137;zz#$d$Ifa$gdqW7%!$IfWD^`gdqW7]kd'$$IflFB"}     4 la1;<RTW}}#$d$&dIfPa$gdqW7 d$IfgdqW7]kdf($$IflFB"}     4 la1WXYZ[#$d$Ifa$gdqW7 d$IfgdqW7]kd($$IflFB"}     4 la1[\biovv$d$&dIfPa$gdqW7%!d$IfgdqW7_kdJ)$$Ifl\FB"}     4 la1opq$%hijo_KPd$If^`PgdqW7d^`gdvN$d^`a$gdvN$d7$8$H$^a$gdvN d^gdvN]kd)$$IflFB"}     4 la1jotuv~~Pd$If^`PgdqW7]kd2*$$IflFp#      4 la1$d$Ifa$gdqW7~~#$d$Ifa$gdqW7Pd$If^`PgdqW7]kd*$$IflFp#      4 la1|m#$d$Ifa$gdqW7#$d$4$Ifa$gdqW7Pd$If^`PgdqW7]kd +$$IflFp#      4 la1~~#$d$Ifa$gdqW7Pd$If^`PgdqW7]kdv+$$IflFp#      4 la1 !&)5;<ABCDoy{}",-Jбť&hghvN>*CJPJaJnH o(tH "hghvN>*CJaJnH o(tH hghvN>*CJaJ&hghvN>*CJPJaJnHo(tHhghvNCJaJ#hghvNCJPJaJnHo(tH hghvNCJPJaJnHtHhghvNCJaJo(2~~#$d$Ifa$gdqW7Pd$If^`PgdqW7]kd+$$IflFp#      4 la1!uu#$d$&dIfPa$gdqW7Pd$If^`PgdqW7]kdZ,$$IflFp#      4 la1!"#$%~~#$d$Ifa$gdqW7Pd$If^`PgdqW7]kd,$$IflFp#      4 la1%&5<Buu$d$&dIfPa$gdqW7Pd$If^`PgdqW7]kd>-$$IflFp#      4 la1BCD|}rccP$d^`a$gdvN$d^a$gdvN$dVD,^a$gd9L$d7$8$H$^a$gdvN $da$gdvN]kd-$$IflFp#      4 la1~]kd".$$IflFp#      4 la1$d$Ifa$gdqW7Pd$If^`PgdqW7 #$,-JKOTUZ\ikotuvw%&CϽϬϬϠϽϠϠϠϠϠϠϠwwwhghQ!CJaJo(hghQ!CJaJ#hghQ!CJPJaJnHo(tHhghvNCJaJo( hghvNCJPJaJnHtH#hghvNCJPJaJnHo(tHhghvNCJaJ&hghvN>*CJPJaJnH o(tH "hghvN>*CJaJnH o(tH .~~#$d$Ifa$gdqW7Pd$If^`PgdqW7]kd.$$IflFp#      4 la1~~#$d$Ifa$gdqW7Pd$If^`PgdqW7]kd.$$IflFp#      4 la1 $*,~~#$d$Ifa$gdqW7Pd$If^`PgdqW7]kdf/$$IflFp#      4 la1,-KOUuu#$d$&dIfPa$gdqW7Pd$If^`PgdqW7]kd/$$IflFp#      4 la1UVWXY~~#$d$Ifa$gdqW7Pd$If^`PgdqW7]kdJ0$$IflFp#      4 la1YZiouuu$d$&dIfPa$gdqW7Pd$If^`PgdqW7]kd0$$IflFp#      4 la1uvw}}hD#9TPL HD@<+{^$>d7$8$H$VDZ^>a$gd9L$dVDJ^a$gdvN$d7$8$H$^a$gdvN]kd.1$$IflFp#      4 la1οtbPbPbt?4hghZiyCJaJ hghZiyCJPJaJnHtH"hghZiy>*CJaJnH o(tH #hghZiy>*CJPJaJnHtH$hghZiyCJOJQJaJnHtH)hghZiy5CJPJ\aJnHo(tHhgh5CJ\aJ)hgh5CJPJ\aJnHo(tHhgh5CJ\aJo(4hghpMSB*CJOJPJQJaJnHo(phtHhghQ!CJaJo(hghQ!CJaJq]kd1$$IflFB "}     4 la1$d$Ifa$gdqW7 %$IfgdqW7dgdZiyd^`gd $d$Ifa$gdqW7 %$IfgdqW7]kd2$$IflFB "}     4 la1 #%&)*9;<afnopѽퟫѐѐџџџ~l~l`ѫhghZiy>*CJaJ"hghZiy>*CJaJnH o(tH #hghZiy>*CJPJaJnHtHhghZiyCJOJQJaJhghZiyCJaJo(#hghZiyCJPJaJnHo(tH'hghZiyCJOJQJaJnHo(tHhghZiyCJaJ hghZiyCJPJaJnHtH$hghZiyCJOJQJaJnHtH%$d$Ifa$gdqW7%!d$IfgdqW7]kd2$$IflFB "}     4 la1$}}#$d$&dIfPa$gdqW7 %d$IfgdqW7]kd2$$IflFB "}     4 la1$%&'($d$Ifa$gdqW7 %d$IfgdqW7]kdh3$$IflFB "}     4 la1()*2:}}$d$&dIfPa$gdqW7 %d$IfgdqW7]kd3$$IflFB "}     4 la1:;<zkk$d$Ifa$gdqW7 d$IfgdqW7 d^gdZiy$d^a$gdZiy]kdL4$$IflFB "}     4 la1$d$Ifa$gdqW7 d$IfgdqW7]kd4$$IflFB "}     4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd05$$IflFB "}     4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd5$$IflFB "}     4 la1(-.34clmlmnruѶ}o}Z)hghPf5CJPJ\aJnHo(tHhgh?5CJ\aJ)hgh?5CJPJ\aJnHo(tHhgh?5CJ\aJo()hghvd5CJPJ\aJnHo(tHhghZiyCJaJo(hghZiyCJOJQJaJhghZiyCJaJ hghZiyCJPJaJnHtH#hghZiyCJPJaJnHo(tH#(.4#$d$Ifa$gdqW7 d$IfgdqW7]kd6$$IflFB "}     4 la145cgm#$d$Ifa$gdqW7 d$IfgdqW7]kdz6$$IflFB "}     4 la1mnyy#$d$&dIfPa$gdqW7d$IfgdqW7]kd6$$IflFB "}     4 la1#$d$Ifa$gdqW7 d$IfgdqW7]kd^7$$IflFB "}     4 la1}}$d$&dIfPa$gdqW7 %d$IfgdqW7]kd7$$IflFB "}     4 la1mnfwwgT$;d^`;a$gd`d^`gd?dgdvd$d7$8$H$^a$gdZiy$d7$8$H$a$gdZiy]kdB8$$IflFB "}     4 la1fghmrst|v]kd8$$IflF$a    4 la$d$Ifa$gdqW7 d$IfgdqW70d^`0gd`ghkmors28BIJPQ %2]clmqv負貏貏貏貏菠農 hgh`CJPJaJnHtH#hgh`CJPJaJnHo(tHhgh`CJaJo(hgh`5CJaJ"hgh`>*CJaJnH o(tH hgh`>*CJaJhgh`CJaJhgh`CJ\aJ8#$d$Ifa$gdqW7 d$IfgdqW7]kd 9$$IflF$a    4 la#$d$Ifa$gdqW7 d$IfgdqW7]kd9$$IflF$a    4 laq#$d$Ifa$gdqW7#$d$4$Ifa$gdqW7d$If^gdqW7]kd9$$IflF$a    4 la#$d$Ifa$gdqW7d$If^gdqW7]kdd:$$IflF$a    4 la#$d$Ifa$gdqW7 d$IfgdqW7]kd:$$IflF$a    4 la #$d$Ifa$gdqW7 d$IfgdqW7]kdH;$$IflF$a    4 la BCJQzzz#$d$Ifa$gdqW7Hd$IfVDXWD8^`Hgd`]kd;$$IflF$a    4 laQRzzz#$d$Ifa$gdqW7Hd$IfVDXWD8^`Hgd`]kd,<$$IflF$a    4 la#$d$Ifa$gdqW7d$If^gdqW7]kd<$$IflF$a    4 la#$d$Ifa$gdqW7d$If^gdqW7]kd=$$IflF$a    4 la zz#$d$Ifa$gdqW7Wd$IfVDWD?^`Wgd`]kd=$$IflF$a    4 la !"#$#$d$Ifa$gdqW7 d$IfgdqW7]kd=$$IflF$a    4 la$%234#$d$Ifa$gdqW7 d$IfgdqW7]kdf>$$IflF$a    4 la45mnrvzzz#$d$Ifa$gdqW7Hd$IfVDWWD8^`Hgd`]kd>$$IflF$a    4 lavw#$d$Ifa$gdqW7d$If^gdqW7]kdJ?$$IflF$a    4 la :;>?BCDLM  ŹŜŐ~j\~\~~hgh`CJ\aJo(&hgh`CJPJ\aJnHo(tH#hgh`CJPJ\aJnHtHhgh`CJ\aJhgheCJaJ#hgh`5CJPJaJnHtHhgh`5CJaJhgh`CJaJ#hgh`CJPJaJnHo(tH hgh`CJPJaJnHtHhgh`CJaJo($#$d$Ifa$gdqW7 d$IfgdqW7]kd?$$IflF$a    4 la#$d$Ifa$gdqW7 d$IfgdqW7]kd.@$$IflF$a    4 lazzz#$d$Ifa$gdqW7d$IfVDXWDj^`gd`]kd@$$IflF$a    4 la;?Cqq#$d$&dIfPa$gdqW7d$IfVDXWDj^`gd`]kdA$$IflF$a    4 laCDLM  jbjO$nWd^n`Wa$gd`dgd`$ & F ;d1$^`;a$gd` d^gd`d^`gd`]kdA$$IflF$a    4 la *+6  p "$'(RWX]^x{|ӽ󠔂veSeveSe#hgh`CJPJaJnHo(tH hgh`CJPJaJnHtHhgh`CJaJo("hgh`>*CJaJnH o(tH hgh`>*CJaJhgh`CJaJ"hgh`CJ\aJnH o(tH &hgh`CJPJ\aJnHo(tHUhgh`CJ\aJo(#hgh`CJPJ\aJnHtHhgh`CJ\aJ customers are State-owned Enterprises. Having due regard to the substance of the relationships, the directors of the Company are of the opinion that none of these transactions is a material related party transaction that requires separate disclosure.(b) As at 31 December 2011, the ultimate holding company provides guarantee to the Group amounted to RMB230,000,000 (2010: RMB230,000,000). (c) Compensation of key management personnelThe remuneration of directors and other members of key management during the year was as follows:20112010RMB000RMB000Short-term benefits2,5665,058Post-employment benefits2422392,8085,297The remuneration of directors and key executives is determined by the remuneration committee having regard to the performance of individuals and market trends.By Order of the BoardShandong Xinhua Pharmaceutical Company LimitedZhang DaimingChairman23 March 2012, Zibo, PRCAs at the date of this announcement, the board of directors comprises: Executive Directors:Mr. Zhang Daiming (Chairman)Mr. Du DepingMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Bai HuiliangMr. Kwong Chi Kit, VictorNon-executive Directors: Mr. Ren FulongMr. Xu Lie Mr. Zhao Bin PAGE PAGE 29"'$d$Ifa$gdqW7 d$IfgdqW7$d^a$gd` nd^ngd`;d^`;gd`nWd^n`Wgd`$;d^`;a$gd` '()19$d$Ifa$gdqW7 d$IfgdqW7]kdA$$IflFd#F    4 la9:;<=#$d$Ifa$gdqW7 d$IfgdqW7]kdbB$$IflFd#F    4 la=>RX^#$d$Ifa$gdqW7 d$IfgdqW7]kdB$$IflFd#F    4 la^_x|}}#$d$&dIfPa$gdqW7 d$IfgdqW7]kd:C$$IflFd#F    4 la#$d$Ifa$gdqW7 d$IfgdqW7]kdC$$IflFd#F    4 la}}#$d$&dIfPa$gdqW7 d$IfgdqW7]kdD$$IflFd#F    4 la45KyzŹuW9#+hghm6B*CJOJQJ]aJph:hghm5B*CJOJPJQJ\aJnHo(phtH:hghzU5B*CJOJPJQJ\aJnHo(phtH+hghm5B*CJOJQJ\aJph%hghmB*CJOJQJaJph4hghmB*CJOJPJQJaJnHo(phtHhgh`CJ\aJhgh`CJaJ#hgh`CJPJaJnHo(tH hgh`CJPJaJnHtHhgh`CJaJo(45Kz}tRRF $ ^ a$gdq"$0TPL HD@< ^ a$$ ^ a$^gdvd$d^a$gd` nd^ngd`]kdD$$IflFd#F    4 laӯկݯޯ ĩ{{bS>S>S>5hghmKH)hghmB*OJPJQJnHphtHhghmB*OJQJph1hghmB*CJOJPJQJaJnHphtH%hghmB*CJOJQJaJph4hghzUB*CJOJPJQJaJnHo(phtH4hghmB*CJOJPJQJaJnHo(phtH4hghpMSB*CJOJPJQJaJnHo(phtH@hghm56B*CJOJPJQJ\]aJnHo(phtH &4EFk{GkdE$$If0!64 a )$$Ifa$ $7$8$H$If)$a$$^a$  &4=>DEFk{ϰа԰ڰܰ朷|lU,hgh{6B*OJPJQJnHo(phtHhghpMSKHPJnHo(tHhghpMSKH,hghmB*OJPJQJnHo(phtHhghmKHaJhghVKHPJnHo(tHhghmB*OJQJphhghqKHPJnHo(tHhghmKHPJnHo(tHhghmKHhgh{6KHPJnHo(tHаܰ#&`#$Gkd_E$$If0!64 a $7$8$H$If )$$Ifa$$7$8$H$IfgdpMS  Ӿ͹ɵhm h0Ao(hg0J$mHnHuh0A h0A0J$jh0A0J$UhjhU+hbhmCJOJPJQJaJnHo(tH#$a$#&`#$# /0P/ =!"#$n% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCBO> NotesdB*CJaJphO Body textc$>TPL HD@<Td1$7$8$H$^Ta$-B*CJOJQJ_HaJmH nHphsH tHHOH Subhead 1Td^T ;CJaJ~O~ Subhead 2B$'PL HD@<Q^`a$5B*\phDZ@D ~e,g$a$CJOJPJQJ aJnHtH<O< write $a$CJPJnHtHpOpChar Char Char Char!d1$CJKHPJaJmHnHtHu.". yblFhe,g"CJaJ6 @26 u#9r G$CJaJ)@A uxP@RP u w%!d1$CJKHOJPJQJaJtH 0b0 le,g&G$CJaJPOrP Anrede' 1$KHOJPJQJaJtH VOV W[CQ W[CQ(d1$CJKHPJaJmHnHtHudOd Default)1$7$8$H$-B*CJOJ QJ _HaJmH nHphsH tH O med1HH  Balloon Text+CJOJ QJ ^J aJ4O4 cke1,B*OJQJph0`@0 HTML 0W@W-6]Be@B  HTML @P h/$<@&a$5CJ OJPJQJ\^JaJ K@ y|T0([@( 5uP[N~{T1\J@"\ oRh2$d8<@&a$"5CJ KHOJPJQJ\^JaJ -2 [e,g43 ` @ 1$3$5$7$8$G$0CJKHOJ PJQJ ^J _HaJmH nHsH tH6%@B6 [ON0W@W4G$ OJQJ^J.?@R. ~_g5dVD4^d4/@b4 Rh68WD8^`8<2@r< Rh 27d8VDWD8^d`8<3@< Rh 38d8VDWD8^d`8<4@< Rh 49d8VDXWD8^d`8<5@< Rh 5:d8VD WD8^d`8,1@, RhS ; & F0:@0 RhS 2 < & F0;@0 RhS 3 = & F0<@0 RhS 4 > & F0=@0 RhS 5 ? & F4D@4 Rhc~@xVD^8E@8 Rhc~ 2AHxVD^H8F@"8 Rhc~ 3BxVDX^8G@28 Rhc~ 4CxVD ^8H@B8 Rhc~ 5D4xVD^400@R0 Rhyv&{S E & F46@b4 Rhyv&{S 2 F & F47@r4 Rhyv&{S 3 G & F48@4 Rhyv&{S 4 H & F 49@4 Rhyv&{S 5 I & F $$vU_ 1J00vU_ 2KVD^00vU_ 3LHVD^H00vU_ 4MVDX^00vU_ 5NVD ^00vU_ 6O4VD^400vU_ 7P VD^ 00vU_ 8Q| VDx^| 00vU_ 9R VD@^ $2$ TybleW[SROAR Ss Char Char1$CJKHPJ_HaJmH nHsH tH*j12* Vybl;NU5\2OBa2 Us Char Char5\(^@r( nf(Qz)W,@@, ~{TXdVD4^d,L@, egYdVD ^dX$@X 6eON0W@W(Zd&+D/G$VDx^d OJQJ^J$ $"}_ 1[0 0"}_ 2\VD^0 0"}_ 3]VD^00"}_ 4^XVDX^X00"}_ 5_ VD ^ 00"}_ 6`VD^00"}_ 7aVD^00"}_ 8bxVDx^x00"}_ 9c@VD@^@6!6 "}_hd5OJQJ\^J8"@8 leCJOJPJ QJ^JaJ4#4 VhvU_f8VDWD8`8(+r( >\le,ggG$>T@> e,gWWhxUDVD]^8Y8 ech~gVi-D M I@ Oo`hoj8$d%d&d'd-DM NOPQVDWD ^8` OJQJ^J0,0 _evU_kVD^<.< _evU_hlxOJPJQJ^J(B@( ckee,gmx4M@4 ckeL)ۏnWDd`8C@8 ckee,g)ۏoxVD^8N@8 ckeL)ۏ 2pWD`0@0 cke)ۏqWD`2P@"2 ckee,g 2 rdx4Q@24 ckee,g 3sxCJaJBR@BB ckee,g)ۏ 2tdxVD^DS@RD ckee,g)ۏ 3uxVD^CJaJ*O@* lʑhv$a$6Oq6 short_text1CJaJ8O8 medium_text1CJaJ4O4 long_text1CJaJvOv T Report Text-z$d1$5$7$8$9DH$^a$KHPJaJmH sH tH JOJ T body text{xx1$CJKHaJtH VOV TRQk=|d1$WD`CJKHOJPJQJaJtH O z hps`` sQ*B* ph@qrtuv"CD "'/08BMXYkr{ >ENVWXYZ[\]7@IRS      @ E I J a x  # 2 3 l z   & ' O ] l t   * ; @ Q R d u  />@OPQRqrw| QV[chi#$V[`hmns8=BGLMgms%)489:?D[pq -.BCU`kz$3@OP"/0BABfg!!!!!!j#k###4%5%&&y'z'''((#)$))),,,,o.p...00;3<3!5"5j5k5_8`899;;;;<<>>??@@(A)ABBCBPBQBCC_D`DDDFFHHII&J'J~KKLLMMMMOOPP6Q7Q R RTTUUoWpWWWWWLXMXXY@YAYZZ+Z,ZZZZZZZZZZZ0[1[2[3[j[q[x[y[[[[[[[[[[[[[\ \\\N\P\W\X\\\\\\\\\\\\\]]]]+]/]3]4]O]P]Q]R]]]]]]]]]^^____``aabbqcrcccd d?f@fOfPfffffBgCgSgTg8i9iiiiiwkxkkkll l%l*l+l,l:lFlSl_l`lylllllllllmm m8mImZmkm|m}mmmmmmmmnn!n/n0nInXnfnunnnnnnnnnnn oo'o5o6oRo`omo{oooooooooooopppeprpppppppppppqq q.q;qyFyGyHyIyJyKyLyqyrysytyuyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy zzz!z"z#zRzSzUzVzWzXzYzZz[z`zezfzgzlztz|z}z~zzzzzzzzzzzzzzzzzzzzzzzzz {!{'{-{.{k{l{u{~{{|||| |I|J|K|Q|W|X|Y|Z|[|\|]|||||||||||||||||||||}}+},}3}:};}U}V}\}b}c}d}e}f}g}h}i}j}q}x}y}z}}}}}}}}}}}}}}}}}}}}}}~~~~~5~6~>~F~G~q~r~z~~~~~~~~~~~~~~~~%&UV]cdefghijkuCDJMN^_ekl€̀ր׀  !"#$%9:;<=VYaij|}؁ف܁ށ߁ #+,OPQRSoprxyz{|}~)*2:;DEOYZrszɃʃ !9:;<=VW]cdopxʄԄՄքׄ45Jjklj<=ۊ܊ŒÌ[\pύ(mnŽÎˎ-.7bcl͏Ώ"56HghzABCΑWݓޓ}~239:¢âBCDEFcd9:WXԦզ֦צ./0=>?EFGOW_gowxyz{|}~çͧΧ &.6>HRSTUVWXYZ[kszѨҨӨԨը֨ߨ !"()*+,-./01DEFGHIPQRSTUVWXYZ~ة٩ک !"#$%&'()*23456789IS[cjlvwĪΪ֪ު"(./789:;<=>?@TUVWXY`avwxyz{«ëīūƫǫͫΫϫЫѫҫӫԫի֭֫׭34ʮ%-./012345DNV^fpqįůƯǯȯɯʯ˯̯)*+,-56789:;<=VWXYZdefz{аѰװذٰ "*2:DEbcdefnopqrstuvı˱ұڱ۱ +,-./9:;!"yz#9UV\]^fnv~ĶʶҶڶ۶+29?FNO)19?CKLflptz[\ ,B^_efgowĺźպۺߺ'/4<EFT]ekoxy޻߻$%&;<I_{|ۼMT[ahpq½ýIJKOPQTUV\]^abcij¾ľƾȾϾо ۿܿ029;=DEU[_clrs %-678QR #$,4<=DLTUVWXYZdnop?@EFG[\]bghiqyz{|}~  !KOUVWXYZ[bijk  !"#2:BCDEFGHOVWX CKSTFJMNx6;ABaeghijklZ[uv DJPQ !"#$%<BHI 07=>dfmnopqrsz KQWX  !"#XYZ[\rsfg$%&'()*2:;<=>?kryz op@ABGLMNV^_`abcs{ !"#^_&./0123CJPQ| "()DFLMjquv PQRW\]^fnopqrs2349>?@HPQRSTUdltu=>?DIJKS[\]^_`px &'( JPVWhlpqrstu 29@AUY[\ !"#KLMNDErs 26:;<=>?@FLMN4BKde%5F`a{000000000000000000000 000000 00000 00000 00000 00000 00000 v00000 00000000 00000$ 00000 00000 00000 00000 0 00000 00 00 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 00 00 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 000 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 00 00 0 00 0 0 0 v 0 0 0  0 0 0  0 0 0  0 0 0  0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0  0 0 0 0 0 0 0  0 0 0  0 0 0 000000000000000000)0000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0 00000000000000 %0 %0 %0 0 0 %0 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 0000 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0  0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0  0 %0 %0 0  0 %0 %0 0  00 %0 %0 0 0 0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 %0 0  0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 000 %0 % %0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 %0 0 0 0 0 %0 0 0 0 0 0 0 0 0 0 0'000000000  0   0   0   0   0   0 0000000000  0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0 000000 00 00000000000000000 0 0  0 0  0 0  0 0  0 0  0 0  0 0 00 00 000 00 0 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 000 00 0 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0  0 0 0 0 0 0 0 0000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0|0 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 000 000 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  %0 0  %0 %0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000 %0 %0 0 0 0 0 0 0 '0 '0 0 0 '0 '0 0  0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 %0 %0 0 0 0 0 0 0 '0 '0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 %0 0 0 0 0000000 %0 %0 0 0 0 0 0 0 '0 '0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 000000 %0 %0 0  0 0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0#0 #0#0 0    0  #0#0 #0#0 0  #0 #0 0 00000 %0 %0 0  0 0 0  '0 '0 0  '0 '0 0  000 000 0 000000000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 % 0 0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 0000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 % #0 #0 0 % #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 00000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 % #0 #0 0 % #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 0 0 0 0000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 0 0 0 0000%0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 #0 #0 0 %0 0 0 0 %0 0 0 0 0000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 00000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0#0 #0 0  #0#0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0#0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0#0 #0 0  #0 #0 0 00 00 000000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 000000000)0)000000 0)000 0 )00)0)0 0 0 0I00I00I00I00I00)I00I00)I00I00,)@#0@#0I0 0 DqI00 I0#$W\X\\\\\K00K00K00K00K00@0 K0 I0h  K0  h  00 %%%(X ,+)\ 5!".#$%'0(') *#+v,-;//0134[8BKU`efg)hhki j|jfkm~ortGv2wmyyy9z  erR"xTmD91ޜQ>ζŷqoxq4~tb,[      .016?FSY_elq}  $4>HOP\bmv| "*-6>NT`bdf>lDq**p)IEv\~P<i&!+H7UJ We4hhh iViqiii jMj`jjjjkdkUo3wyy9zzzX{{{?|||;}}~c~~ z#v܀0c1 *߄ +0PmȅGLo†dž?DV[`҇',VӉ؉!&^cҊ*7Lc‹$M~ߌ1aɍ6;R8ZrΏ 6;w|ՐEotߑ!49P16>_ߜI%~"\n0Գô I^εеֵ+7M[jx̶ζԶֶkmŷ028@vx~иܸ>IKQert# @CHSU}߾V{ @W1~ .Ah46)/ey/?|>L|ak!BZuXjn E "?["&IMJ2{CXcg BGA&h9$(U?CSW7p;W[oj!%B,UYu$(:4mf Q $4vC'9=^ !"#$%&'()*+,-/2345789:;<=>@ABCDEGHIJKLMNOPQRTUVWXZ[\]^`abcdfghijkmnoprstuvwxyz{|~   !"#%&'()*+,-./012356789:;<=?@ABCDEFGIJKLMNQRSTUVWXYZ[]^_`acdefghijklnopqrstuwxyz{}~    !#$%&'()+,./012345789:;<=?@ABCDEFGHIJKLMOPQRSYZ[\]^_aceg;U_UmUX !(!!t  ,b$l?xK-}*1@ (  t  c 6A!SHANDON"?B S  ?H0(  r]t OLE_LINK6 OLE_LINK13 OLE_LINK14 OLE_LINK100 OLE_LINK101 OLE_LINK12 OLE_LINK15_Hlk252804176 OLE_LINK3 OLE_LINK30 OLE_LINK28 OLE_LINK29_Hlk252956248|ůů@@\\\pQQQ   |̯̯DDhhhlA]]]^1^1^#tdsd<*urn:schemas-microsoft-com:office:smarttagschmetcnv ,01 30731283060730000aFalseHasSpaceinNegative NumberType SourceValueTCSCTrueUnitName      vJTv%%%%)),,--////0#0x1~1 2222234477P:S:T:_:e:h:i:t:_<g<z<<0?9?i?t?u??@@BCEE,P2PUUUUZZ[[t`}`aapdydzddjjΓۓ_iak)| )3Q]hr-7_i5<P]:A-49<=EJOsjk>]S @ 3 l ' O Qi$Vmn8%_`P0pWWZZj[y[[[[\N\X\\\]]+]R]]]]]CgTgl9l:loopepqqr@ssst+uQuuuuuvwwwwwwxxxxLyuyy zRz[zz!{.{l{{| |K|]|||||}z}}~~5~6~G~r~~~~~~~&VD׀فSp)*VWopՄJlj\pύ(nÎ7cΏzQFdצ"Zǫ;۶+O) &ۼMqýKOQTV\^acjsRpG!K12X CTFNx6Bal[v QI0>d KX#g?kzB"Q|vR24u?'J \NNKe%5F{|0b?}8.>~ڟL=R<4-I:H VG>wC>Z>O%?Y?:R@^@xn@% AH3A6XA{kACBa,Ca1C6D7DinD4EJE0F`)F;FG)G>HH7H->HxWHpHaIIzK2UAJW=]=^?ju #(?u18Iu) L ]$:'1`,-DrO%00<b*I,CS]qk@)rJYZeg (oE &^,u7r:LO .FpLdV E;z)f;sB\u6`V aZBpUroAsxyCh|{6Tkm8gIKUkv>_`$vHhNW}kKp:Pob{"/08BMXYkr{ >ENVW7@IRS   @ I J a x  # 2 3 l z   & ' O ] l t  * ; @ Q R d u  />@OPqrw QV[chi#$V[`hmns8=BGLMgms)89:?D[pq -.BCU`kz$3@OP"/0ZZZZZZ0[1[2[3[j[q[x[y[[[[[[[[[[[[[\ \\\N\P\W\X\\\\\\\\\\\\\]]]]+]/]3]4]O]P]Q]R]]]]]]]]]ll l%l*l+l,l:lFlSl_l`lylllllllllmm m8mImZmkm|m}mmmmmmmmnn!n/n0nInXnfnunnnnnnnnnn oo'o5o6oRo`omo{oooooooooooopppeprpppppppppppqq q.q;qyFyGyHyIyJyKyLyqyrysytyuyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy zzz!z"zRzSzUzVzWzXzYzZz[z`zezfzgzlztz|z}z~zzzzzzzzzzzzzzzzzzzzzzzzz {!{'{-{.{k{l{u{~{{|||| |I|K|Q|W|X|Y|Z|[|\|]|||||||||||||||||||||}}+},}3}:};}U}V}\}b}c}d}e}f}g}h}i}j}q}x}y}z}}}}}}}}}}}}}}}}}}}}}}~~~~~5~6~>~F~G~q~r~z~~~~~~~~~~~~~~~~%&UV]cdefghijkuCDJMN^_ekl€̀ր׀  !"#$%9:;<=VYaij|}؁ف܁ށ߁ #+,OPQRSoprxyz{|}~)*2:;DEOYZrszɃʃ !9:;<=VW]cdopxʄԄՄJjklj[\pύ(mnŽÎˎ-.7bcl͏Ώ"56HghzABBCDEFdԦզ֦.=EFGOW_gowxyz{|}~çͧΧ &.6>HRSTUVWXYZ[kszѨҨӨԨը֨ߨ !"()*+,-./01DEFGHIPQRSTUVWXY~ة !"#$%&'()*23456789IS[cjlvwĪΪ֪ު"(./789:;<=>?@TUVWXY`avwxyz{«ëīūƫǫͫΫϫЫѫҫӫԫի֫ʮ%-./012345DNV^fpqįůƯǯȯɯʯ˯̯)*+,-56789:;<=VWXYZdefz{аװذٰ "*2:DEbcdefnopqrstuvı˱ұڱ۱ +,-./9:#9U\]^fnv~ĶʶҶڶ۶+29?FNO)19?CKLflptz ,B^efgowĺźպۺߺ'/4<EFT]ekoxy$%&;I_{ۼMT[ahpq½ýIOT\aij¾ľƾȾϾо029;=DEU[_clrs %-67 #$,4<=DLTUVWXYZdno[\]bghiqyz{|}~  !KOUVWXYZ[bij  !"#2:BCDEFGHOVW CKSTFJMNx6;ABaeghijkl DJPQ !"#$%<BHI 07=>dfmnopqrszKQWX  !"#XYZ[$%&'()*2:;<=>?kryz@ABGLMNV^_`abcs{ !"&./0123CJPQ| "()DFLMjquvPQRW\]^fnopqrs2349>?@HPQRSTUdltu=>?DIJKS[\]^_`px &' JPVWhlpqrstu 29@AUY[\ !"#KLMN 26:;<=>?@FLMe`a!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!7!708 @( |vvvvv9v:UV`@` `@``4@`D`@`b`@`X@Unknown Lenovo UserG0536UserGz Times New Roman5Symbol3& z ArialC .PMingLiUe0}fԚU.{ @CalibriCentury Gothic;[SOSimSun3Times] Times-BoldTimes New Roman[ (DFPFangSongW4-B5PMingLiU;ўSOSimHei?5 z Courier New;& Helvetica5& zaTahoma;Wingdings FA%%!xxd&&2qHX?8|2 2006 ANNUAL RESULTS ANNOUNCEMENTWonderful SkyhggSfP            Oh+'0(8 HT t  $2006 ANNUAL RESULTS ANNOUNCEMENTWonderful Sky$generated by an Adobe applicationNormal488Microsoft Office Word@8@9@Tb@ L%՜.+,D՜.+,  `h Wonderful Skyx&  8@ _PID_HLINKSAdYhttp://www.ebnew.com/  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}     "#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNPQRSTUVXYZ[\]^kRoot Entry FmmData ~E1Table![WordDocumentSummaryInformation(ODocumentSummaryInformation8WCompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q